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   ii 
Abstract 
 
A major challenge in the long-term management of HIV is drug resistance caused from high rate 
and error prone viral replication. To examine mechanisms of drug resistance within HIV-1 protease 
complexed with Darunavir, specific point mutations were placed in the protease amino acid sequence and 
molecular dynamic simulations were run. Darunavir was chosen as the modeled ligand as it is the most 
potent protease inhibitor commercially available. MATLAB and python scripts were developed to 
efficiently and consistently analyze simulation data. The team hypothesized that there would be a 
difference in inhibitor interactions and protein dynamic behavior in mutant variants compared to wild 
type. Although some aspects of increased resistance were seen with compounded mutations, overall this 
trend was not observed across every facet of our analysis.   
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Executive Summary 
 
Human immunodeficiency virus (HIV) is a global epidemic, negatively affecting the quality of 
human life since it’s peak of public awareness during the 1980’s [3]. HIV is a retrovirus that has evolved to 
target and destroy the cells that make up the human immune system, specifically CD4 T-cells.  After HIV 
has destroyed the majority of the body's immune system, the disease is reclassified as acquired 
immunodeficiency syndrome (AIDS), where the risk of co-infection with other viruses is high and often 
fatal.    
Currently, HIV-1 remains a non-curable disease that requires a strict regimen of antiviral drugs to 
prevent disease progression. With nearly 37 million infected and 2 million new cases annually world wide, 
the need for more potent treatment or a cure is escalating [4]. Further there is an estimated 1.2 million 
Americans living with HIV-1, the viral serotype found in the Western world [5]. The FDA has approved 
25 different antiviral drugs, with 7 classes that each target different stages of HIV-1’s life cycle [6]. 
Protease inhibitors are a class of potent antivirals normally used in late stage, severe cases of HIV-1 
infection. These are competitive inhibitors that prevent HIV-1 protease from cleaving viral polyproteins, 
inhibiting virion maturation. However, HIV-1’s high rate of replication, lack of error-proof mechanisms, 
and selective pressures in response to drug presence promotes drug resistance [7, 8]. Drug resistance is a 
result of amino acid mutations that alter the shape of the proteins binding pocket such that a drug cannot 
bind properly and maintain functionality.  Normally, mutations causing drug resistance are located within 
the active site, as well as non-active site regions of the protease. Active site mutations directly impact 
inhibitor binding and non-active site mutations affect the tertiary structure [7]. The team hypothesized that 
active mutations involved in drug resistance follow an additive trend. 
Through discussion with the client, the team chose three active site mutations for the team to 
analyze. These mutations are resistant variants of HIV-1 protease found in HIV-1 infected mouse models. 
The first resistant variant was a single amino acid mutation of residue 84 from an isoleucine (I) to a valine 
(V), notated I84V. The second resistant variant was a double amino acid mutation of I84V and the amino 
   xii 
acid mutation of the residue 82 from a valine (V) to a phenylalanine (F), notated V82F. The third resistant 
variant was the triple amino acid mutation involving mutations I84V, V82F, and an amino acid mutation of 
the residue 46 from methionine (M) to isoleucine (I), notated M46I.  
Computational analysis, specifically molecular dynamics (MD), was selected to simulate the 
protein’s dynamic behavior. The data from MD simulations can be used to analyze the effects of these 
mutations on the ability of the inhibitor to bind to the active site. First, the team modified crystal 
structures of the protein using molecular modeling software (Schrodinger’s Maestro) to generate point 
mutations. A water system (TIP3) and force field system (OPLS_2005) were added, and the protein 
system was minimized to the lowest energy state ("native" folded conformation). The modified model is 
then imported into molecular dynamic software (Desmond) to simulate the protein system for 100 ns, 
which gives enough time for the protein system to equilibrate to 300K and provide an accurate analysis of 
its dynamic behavior. A Wild Type crystal structure without an altered protein sequence was also 
generated and simulated under the same conditions to serve as a control. 
Three 100- nanosecond simulations were conducted for each mutation and Wild Type models. 
The simulations provide atom-coordinates and energies of the protein system over the 100 nanoseconds. 
The data from the simulations is further analyzed by other programs, such as scripts for VMD and 
Schrodinger’s Maestro, to gather the protein’s C-alpha root-mean square deviations (RMSD), protein 
residues’ and ligand atoms’ root-mean square fluctuations (RMSF), van der Waal energies and hydrogen 
bonds between the ligand and protein. 
The process of compiling and comparing these analyses across mutations was inefficient and 
difficult. Therefore, the team developed scripts in MATLAB and Python to increase the efficiency and 
effectiveness of analysis. The scripts standardized the data across mutations, generated visualizations of 
the data and allowed the adaptability for future analyses.  
Average Protein RMSF was compared to the Wild Type average and the absolute difference was 
summed. V82F+I84V had the greatest absolute difference, followed by I82V and M46I+V82F+I84V. 
Additionally heat maps were generated showing differences compared to Wild Type with a color gradient 
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ranging from red as a maximum and blue as a minimum. Similar to Protein RMSF, Ligand RMSF was 
compared to the Wild Type average and the absolute difference was summed. In the case of Ligand 
RMSF, an additive trend was observed with resistance increasing from the single mutant variant to the 
double mutant variant with an increase in fluctuation of 0.07 Angstroms. Additionally the triple mutant 
showed greater resistance compared to the double mutant with a fluctuation increases of 0.23 Angstroms. 
Hydrogen Bond percentages of each mutation were subtracted from the Wild Type percentages and 
summed. Hydrogen Bond percentages followed a different trend than the previous analyses with 
M46I+V82F+I84V retaining the most bonds. In the case of double mutation variant, the Wild Type had a 
significantly greater bond character.  As expected, the mutated variants had less van der Waals 
interactions with the inhibitor. I84V had the fewest attractions with a summed difference of -3.63 
kcal/mol compared to WT. V82F+I84V and M46I+V82F+I84V had similar van der Waal interactions 
with summed changes of -2.031 and -2.032 kcal/mol, respectively. 
Ligand RMSF data supports our hypothesis; however, further analysis displayed inconsistent 
trends with drug resistance. M46I+V82F+I84V showed the most inhibitor fluctuation, followed by 
V82F+I84V, and I84V demonstrated the least amount of inhibitor movement. However, in the case of 
Protein RMSF, van der Waal interactions and hydrogen bond percentages, additive behavior is not 
supported. Van der Waal interactions provided inconclusive data, with I84V and V82F+I84V having a 
similar amount of interactions. With respect to Protein RMSF, V82F+I84V had the greatest fluctuation 
compared to Wild Type, followed by M46I+V82F+I84V, then I84V. Similar to Protein RMSF, 
V82F+I84V demonstrated the highest percentage of hydrogen bonds, followed by M46I+V82F+I84V, 
then I84V. This however, partially supports the hypothesis, as V82F+I84V and M46I+V82F+I84V appear 
to be additive. 
To further support the conclusions of this project, the team suggests MD analysis of additional 
compounded mutations within the active site. Also, examining different environmental backgrounds can 
strengthen future correlations. Finally, the data generated from this project can be used in the 
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development of protease inhibitors that are designed to retain potency across compounded mutations that 
may confer additive resistance. 
 
   1 
1.0   Introduction 
Human immunodeficiency virus (HIV) has been a major epidemic affecting roughly 34 million 
people worldwide [4]. Out of the 34 million, there are approximately 1.2 million people in the United 
States currently living with HIV [5]. Up to $19.1 billion dollars has been spent annually to support HIV 
treatments in underdeveloped countries, where HIV infections are most prevalent [9]. Developed 
countries, such as the United States, have been able to limit the spread of HIV-1, the most common 
serotype, through education, awareness and readily available antiretroviral therapies.   
HIV is categorized as a retrovirus, which has the ability of integrating its viral genome into the 
genome of the host cell [10]. Once the viral genome is incorporated into the host cell's genome, the virus 
uses the host cell’s internal components to replicate, propagating the viral genome. A common method to 
treat retroviruses is inhibiting certain steps of the HIV viral life cycle, such as inhibiting HIV-1 protease 
for HIV. HIV-1 protease is a protein that cleaves synthesized polyproteins essential to the maturation of 
HIV [11]. Protease inhibitors are small molecules that can bind themselves in the active site of protease 
and cause protease to lose its functionality. Currently there are six different classes of drugs to treat HIV 
and the course of treatment normally consists of a “cocktail” of two or more drugs [9]. 
The major challenge in effectively treating HIV is the rate at which the virus mutates [7]. The two 
factors that cause high mutation rates throughout HIV replication are the short life cycles of the virus and 
the use of RNA as the genetic makeup. When mutations occur within the 198 amino acids that protease is 
composed of, the protein's three-dimensional structure will be altered. Current protease inhibitors are 
designed to inhibit HIV protease that do not have an altered structure. This results in resistance to the 
protease inhibitor over the course of HIV replication cycles.   
To combat this issue of drug resistance, antiretrovirals are currently administered in combination 
known as highly active antiretroviral therapy (HAART) [12]. HAART therapy is the current gold 
standard for HIV management. However, there may be systemic side effects such as hepatotoxicity, 
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kidney stones, and increased cholesterol levels [10]. When a patient is on HAART therapy, they reach a 
level of clinical latency. Over time therapy can become less effective, HIV levels in the blood stream will 
rise and CD4 cell counts will begin to fall. 
Decreases in therapy effectiveness can potentially be improved by better understanding the 
mechanisms of drug resistance. This project aims to analyze drug resistance variants of the HIV-1 
protease and develop patterns of drug resistance based on mutations. These mutations will be established 
from studying simulations of protease mutations and wild type HIV-1. Specifically, comparing mutated 
variants to the wild type using molecular dynamic principles are within the scope of this project. The 
potency of inhibitor therapies of each mutation will be quantified by analyzing mutated variants and wild 
type interactions with the inhibitor. 
This project developed analysis software to effectively and consistently analyze the effect of 
mutations within HIV-1 protease on inhibitor interactions. Scripts were developed to determine the 
fluctuation within the protein and ligand, the alpha-carbon distance to track movement and changes in the 
active site. Additionally, hydrogen bonds and van der Waals interactions in the presence of Darunavir, the 
most potent protease inhibitor commercially available, were examined. By considering all of the above 
aspects of drug resistance, conclusions on the effect of each mutation on inhibitor effectiveness were 
drawn.  
Future implications of the conclusions drawn through this project allow for the reverse 
engineering of novel protease inhibitors. Improved inhibitors can be developed through protein 
engineering, which is the design of a new protein or enzyme that has novel or desirable functions [13].  
Protein engineering will be applied to this project by computationally developing new mutated HIV-1 
protease structures by homology modeling. The mutated HIV-1 protease will have one amino acid 
replacement compared to the wild type. Mutations will be modeled using molecular dynamic software, 
and movement of the protein will be compared to the wild type.  
By focusing on future mutations, drug designs should have a higher efficacy than existing market 
therapies and multiple inhibitors are no longer needed. From the potency data gained comparing the 
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effectiveness of existing therapies, the type and rate of release required will be considered. Simulating 
HIV-1 protease mutations and applying molecular dynamic principles will provide an understanding of 
the functionality of the protease, as well as allow future mutations to be predicted. An adaptive analysis 
model may provide further drug resistance correlations leading to an improved approach to protease 
inhibitors.    
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2.0   Literature Review 
2.1   Human Immunodeficiency Virus 
HIV, which stands for human immunodeficiency virus, is a virus that infects the host’s immune 
cells [3]. These immune cells are typically T cells that have CD4 receptors, of which HIV binds to, on 
their surfaces. HIV can eventually lead to AIDS, Auto Immune Deficiency Syndrome, and eventually 
death from co-infection. The world is currently experiencing an HIV/AIDS epidemic with about 37 
million people infected, 2 million newly infected, and a mortality rate of 1.2 million in the year 2014 [4]. 
With a large population infected with HIV and continuous new cases of infection, the need for more 
potent treatment or a cure is escalating.  
 HIV is a retrovirus and there is no cure to eradicate the virus permanently. Instead, there are 
several antiretroviral drugs that repress the virus by slowing down its replication and infection rate into 
the target cells, which are the immune cells for HIV. Currently, there are 28 FDA-approved antiretroviral 
drugs available to patients for the repression of HIV [6]. Unfortunately, there are two main problems 
associated with these drugs, resistance and administration. There is a need to further understand these 
resistance mechanisms and develop a new drug or method to make the current antiretroviral drugs 
effective towards the resistant variants. The second problem is that the delivery of this drug to the body is 
not ideal. This includes the lack of convenience and adherence to taking the drugs, the toxic side effects, 
and the limited entry options of the drug to the body [10]. 
2.1.1   Clinical Relevance 
There have been large financial investments made in treatment research. The therapy is required 
to be taken for the entirety of a patient's life and several people, especially in under developed countries, 
are unable to afford or obtain it [6]. Research so far has developed the 28 FDA-approved antiretroviral 
drugs and has increased the knowledge about the virus and its mechanisms. However, research still needs 
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to continue to better understand the interactions between the virus and the host, in order to provide 
alternative drug delivery methods. 
 Recognizing these needs, our project involves researching drug resistance patterns to achieve a 
better understanding of the virus and its mechanism to resist current drug therapies. From this research, a 
predictive model of mutations is to be designed that can be used in alternative drug design. 
2.1.2   Viral Structure and Life Cycle 
HIV is an enveloped virus with several types of proteins embedded on the surface [14]. Two 
glycoproteins, gp120 and gp41 exist connected on the cell surface and are vital to viral entry [15]. Viral 
gp120 binds to the host protein receptor CD4, found on leukocytes, namely T lymphocytes. In addition to 
binding to the CD4, the virus must also bind to a chemokine co-receptor, CCR5. Binding to the CD4 and 
CCR5 receptor and co-receptor triggers fusion of the viral and host membranes through gp41. Gp41 
consists of three primary domains: the intra-envelope domain, trans-envelop anchor and the extra-envelop 
domain. The extra-envelop domain is directly involved in the fusion process and is made of two 
hydrophobic heptad repeats, HR1 and HR2, and a hinge region. Upon binding and inserting fusion 
peptides into the host membrane, gp41 dissociates from gp120, causing gp41 to fold into a hairpin 
structure. The heptad repeats lie anti-parallel forming a 6-helix bundle, promoting the fusion and entry of 
HIV. The figure below displays the mechanism of how HIV attaches to the host cell and fuses together 
for the delivery of its RNA (Fig. 2.1). 
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Figure 2. 1: Attachment/Entry and Fusion of HIV to the host cell [14] 
 
Two proteins, gp41 and gp120, from the surface of the HIV virus stretch and bind to the host 
cell’s membrane (pre-hairpin Intermediate) [14]. The connection then brings the membranes closer 
together (hairpin) to allow for fusion and entry of the HIV’s RNA into the inside of the host cell (post-
fusion).  There are possible interactions at the pre-hairpin intermediate to inhibit the cell membranes to 
draw closer together (hairpin). These would stop the fusion of HIV and the host cell, thus a possible 
therapeutic treatment of HIV. 
The next step of the cycle is reverse transcription that entails HIV RNA converting to DNA [16]. 
The enzyme reverse transcriptase (RT) is a heterodimer with a p51 and p66 subunit. The p66 subunit has 
catalytically active DNA polymerase and RNase H domains that both are responsible for converting the 
single-stranded RNA into double-stranded DNA. The first process involves using the viral RNA genome 
as a template for the host-cell transfer RNA to make a minus-strand DNA. This results to a RNA/DNA 
hybrid that the RNAse H domain cuts into several short RNA segments. Two of these RNA segments are 
polypurine tracts (PPTs) that start the synthesis of plus-strand DNA, which comes together with the 
minus-strand DNA to form a double-stranded DNA viral genome. The RNase H removes the PPTs from 
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the DNA and exposes the integration sequence, which will be used for the integration step of HIV’s life 
cycle. These processes of RT have to be followed precisely or integration will be prevented. 
For HIV DNA integration, the DNA needs to integrate itself into a chromosome of the host cell 
[17, 18]. The enzyme integrase (IN) catalyzes the process of the viral DNA to inserting itself into the host 
chromosome. The first step of the process is IN trimming two nucleosides from the DNA. Next the IN 
stays bound onto the DNA and other viral proteins come together with IN to form a complex known as 
pre-integration complex (PIC).  These viral proteins are reverse transcriptase (RT), MA, CA, and other 
accessory proteins. The PIC connects both ends of the DNA and travels through the cytoplasm to the 
nuclear membrane. It easily goes through the nuclear membrane because of its karyophilic properties due 
to the protein importin 7 and TNPO3. Another protein NUP153, which regulates nucleocytoplasmic 
trafficking, is a cellular protein that also helps the PIC to cross through the nucleus. Once the complex is 
in the nucleus, the integration of the DNA into the host's DNA starts. A large number of proteins are 
involved in this process that include HMGA1, BAF, Ku, LEDGF, HAT P300, HAT GCN5, LAP2-alpha, 
Emerin, JNK/Pin1, RAD51, and KAP1. After integration, there are some post-integration steps that allow 
gene expression and virion production. The proteins involved in those processes are INI1, VBP1, 
Daxx,transcription regulators/chromatin binding factors, and Huwe1. Any of these proteins are possible 
targets for therapeutic inhibition, but mechanisms of some proteins are better understood than others and 
thus are more likely a target for inhibition. 
After integration, the host cell goes into a resting period known as resting peripheral blood 
lymphocytes (PBL) [19]. PBL is a state at which HIV-infected host cells have the HIV genome in the 
DNA but is not expressed yet. The PBL state is also known as the state of latency for HIV-infected 
patients. PBL state continues until a set of cellular factors interacts with amino acid sequences at the HIV 
long terminal repeat (LTR). The main cellular factor that initiates transcription is NF-κB, which is a 
protein with p50 and p65 subunits. P65 leads the transcriptional activity of the HIV genome in the 
immune cells’ nuclei. 
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Transcription involves splicing the produced RNA into 46 sections. The spliced RNAs include 
the fully spliced mRNAs, which include Tat, Rev, and Nef, and the single spliced mRNAS, which include 
Vpu, Vpr, Vif, and Env [20]. Tat enhances the expression of the HIV genome via elongation of viral 
transcriptions with TAR, SP1, NF-κB, and other cellular factors [19]. Tat works with other proteins, 
cyclin T1 and PCAF, to increase HIV transcription and its quality [21]. Additionally, an enzyme human 
sirtuin 1 (SIRT1) recycles Tat in order for transcription to continue. The other mRNAs are responsible for 
other functions later in the HIV life cycle. 
Another step of the HIV-life cycle is the assembly of the retrovirus particles, which is also known 
as packaging or encapsidation. In charge of this step are two strands of genomic RNA. These strands of 
RNA interact with the polyprotein Gag, which is the main structural polyprotein of HIV-1 capsids, and 
the ψ (packing signal) portion of the RNA [22]. Gag is 55 kDa and consists of four major subdomains. 
These subdomains include matrix (MA), capsid (CA), nucleocapsid (NC), and p6. The Gag protein is 
illustrated in Figure 2. The NC region of Gag bridges together the individual Gag monomers by gRNA 
(genomic RNA). The NC portion of Gag specifically binds to the ψ portion of the RNA to facilitate RNA 
packaging into virus particles [1, 20]. Further, the ψ portion of the RNA has four stem-loops (SL1-SL4). 
SL1 mediates RNA dimerization, SL2 and SL3 bind to the NC, and SL3 directs packing of heterologous 
RNAs [1]. 
 
 
 
 
 
 
 Once these RNAs, glycoproteins of the virion envelope (Env), viral structure enzymes (Gag), and 
viral enzymatic proteins (Pol) all assemble, the budding of the HIV viral particle is initiated [23]. The 
Gag proteins organize these proteins and protect them in an inner viral membrane. MA is the matrix layer 
of the inner viral membrane, the NC provides a nucleocapsid layer around the viral RNA genome, and 
Figure 2. 2: Gag Polyprotein Domain Structure. Shows the MA, CA, NC, and p6 protein sections [1] 
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CA is the conical capsid surrounding the nucleocapsid, RT, and IN. P6 gathers the cellular components 
and Vpu support virus release needed for viral budding. 
After budding, CA proteins reassemble to form a mature virus [24]. The capsid adopts a cone 
shape with the help of the envelope proteins. Also the NV/RNA complex condenses to the center of the 
core and genomic RNA dimer becomes more stable. A 5% ribosome shift of the C-terminal of gag results 
to a Gag-Pol protein when translated. The Gag-Pol protein encodes the information for producing a viral 
protease (PR). The PR slices the CA proteins so they can assemble into a mature virus. Once the virus is 
mature, the virus is able to infect other immune host cells and create more viruses. 
2.2   Current Therapies 
           HIV antiviral medication targets the specific stages of the viral life cycle: fusion into the host, 
integration of viral genome into the host, translation of viral RNA and maturation of the virus following 
budding. Each inhibitor works in an independent fashion by various mechanisms to achieve the common 
goal of rendering the HIV virus nonfunctional and prevent CD4 cell destruction.   
2.2.1   Fusion Inhibitors 
The first class of HIV antiviral medication is fusion inhibitors, which prevent the entry of the 
virus into the host cell. There are five classes that block various stages of the fusion process: binding 
peptides to the heptad repeats 1 (HR1), binding peptides to the heptad repeats 2 (HR2), peptide-mimetic 
inhibitors, non-peptide inhibitors and CCR5 antagonists [15, 25]. Fusion inhibitors are infrequently 
prescribed, especially in early stage antiviral therapy. Among the fusion inhibitor classes, the most 
commonly prescribed and most effective are the peptide sequences that bind to HR1 and HR2. This 
review of available fusion inhibitors focuses primarily on the successful HR1 and HR2 binding 
inhibitors.    
The first class is made of inhibitors that are successful by binding peptides to the HR1 [15].  
However, only one fusion inhibitor, T20, is FDA approved and available on the market, while the 
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remaining are still under development. T20 or Enfuvirtide, is a peptide sequence that is derived from the 
HR2 amino acids that binds to the HR1. This binding prevents interactions with the HR2 that are 
necessary to create the 6-helix bundle. T20 has a half maximal inhibitory concentration (IC50) of 1.0 nM. 
Second generation peptide sequences that bind to HR1 have been explored. One example, C34, utilizes 
the same mechanism as T20 but only uses non-overlapping targets, where T20 targets may overlap. 
Further, the C34 sequence has a higher potency than T20, with an IC50 = 3.0 nM. An additional second 
generation HR1 targeted peptide that provides promising inhibition is T1249. This peptide offers high 
potential as it has been proven to be effective in both HIV-1 and HIV-2 types. Additionally, T1249 is 
more potent than T20, likely due to the fact that it binds to more targets, and has shown to be effective 
against HIV strains that are resistant to T20. Resistance often arises to this class of fusion inhibitors, as 
T20 and C34 only target 8-10 amino acids, and any mutations to the HR1 often render the inhibitors 
ineffective. 
The second class of fusion inhibitors works in a similar fashion and is composed of peptide 
sequences that instead bind to the HR2 [15]. T21 is a synthetic 38 sequence N-peptide that is derived 
from HR2 amino acids. The first 25 amino acids in the peptide bind to the HR2 and is more potent than 
HR1 targeting peptides, with IC50 = 2.7 uM. Another HR2 targeted peptide is N36, which is a 36 amino 
acid sequence that is derived from HR1 amino acids. N36 has an IC50 = 308 nM, but also has two 
derivatives with 9 amino acid substitutions. These derivatives have been proven to be more effective than 
the parent N36 with IC50 = 16 uM. 
Peptide-mimetic fusion inhibitors are large hydrophobic protein-like chains that have exhibited 
anti-HIV potential with an IC50 = 10.4 uM [15]. However, due to the hydrophobicity of peptide-mimetic 
molecules, their binding capacity is enhanced with trapping agents. Additional development with bind 
mechanisms and trapper agents are needed to promote the use of peptide-mimetic inhibitors. Non-peptide 
fusion inhibitors are another class of fusion inhibitors that have been developed, yet are not widely used. 
These inhibitors are a non-binding approach target at the heptad repeats to block the 6-helix bundle 
formation. Lastly, CCR5 antagonists bind to the CCR5 co-receptor to block CCR5 signaling. 
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2.2.2   Integrase Inhibitors 
Integrase inhibitors are a smaller class of inhibitors that prevent the insertion of viral DNA into 
the host cell's regular genome [26, 27]. Host cells do not contain an integrase equivalent, therefore there is 
an increase in targeting efficiency and no interference with normal cellular function. Integrase inhibitors 
work to prevent the insertion of viral DNA through a two-step process. First, the 3' endonucleolytic 
processing of viral DNA is blocked. The second portion of integrase inhibition is preventing strand 
transfer, which is the joining of host and viral DNA. Divalent metals, such as magnesium ions, are 
required for both 3' processing and strand transfer, and is often the mechanism of integrase inhibitors. 
The primary class and first true class of integrase inhibitors with no entry inhibitor mechanism is 
4-Aryl-2,4-diketobutanoic acids (DKA) [27]. DKAs interact with the divalent metals in the active site, 
resulting in chelation of critical metals, rendering viral integrase nonfunctional. The most competitive and 
first FDA approved integrase inhibitor on the market is Raltegravir, which resulted from optimizing 
original DKA formulations. Raltegravir improved the metabolic stability, drug release profile and potency 
drawbacks of original DKAs with an IC50 of more than 50 uM, making it a more potent therapy than entry 
inhibitors. 
2.2.3   Nucleoside Reverse Transcriptase Inhibitors 
Nucleoside reverse transcriptase inhibitors (NRTIs) are the third class of inhibitors that work to 
prevent transcription and replication of the viral genome [28]. NRTIs competitively incorporate into 
nascent viral DNA through substrate binding. Lacking a 3' OH group, NRTIs successfully bind in place of 
viral reverse transcriptase and terminate the chain. However, the major challenge with NRTIs is the 
competition with natural dNTPs for recognition and catalysis in order to prevent DNA synthesis. 
One example of a NRTI is Zidovudine, marketed under the brand name Retrovir. It was the first 
HIV antiviral to be approved by the FDA in 1987 [29]. However, Retrovir is primarily used in the 
treatment of maternal to infant transmission of HIV or in combination treatments.  
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2.2.4   Non-Nucleoside Reverse Transcriptase Inhibitors 
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are similar to NRTIs, however, they 
are noncompetitive and target HIV-1 reverse transcriptase at a non-substrate binding site [12]. They are 
highly active against HIV-1, but cannot target HIV-2 or other retroviruses. Additionally, the major 
drawback of NNRTIs is they are notorious for triggering drug resistant variants. 
There are two main classes of NNRTIs, which target either an allosteric or TIBO binding site 
[12]. 1-(2-Hydroxyethoxymethyl)-6-(phenylthio)thymine (HEPT) targets the allosteric site to disrupt 
enzyme activity and is functionally related to the binding site of HIV reverse transcriptase. The primary 
disadvantage of HEPT analogue NNRTIs is there is enhanced likelihood of resistance mutations. The 
second class, 4,5,6,7-Tetrahydroimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-one or TIBO, targets the 
TIBO binding site. 
2.2.5   Protease Inhibitors 
The final class of HIV inhibitors is protease inhibitors. They prevent the cleavage of the viral 
polyprotein chain, which blocks the maturation of the virus following budding from the host cell. There 
are a total of eight protease inhibitors on the market, however the two newest and most frequently used in 
combination therapy are atazanavir and darunavir. 
Original protease inhibitors became FDA approved in the 1990s, including saquinavir, ritonavir, 
nelfinavir and indinavir [30]. These first generation were successful but had major limitations. These 
included low potency, several severe side effects and complications. 
Approved in 2003, atazanavir was one of the first second generation protease inhibitors [11]. In a 
study conducted by Molina et al., atazanavir was proven to be a potent inhibitor, especially when boosted 
with ritonavir. The study utilized patients who had not yet received atazanavir or ritonavir antiviral 
treatment. 82% treated with a combination of atazanavir and ritonavir responded to treatment and had 
plasma counts less than 50 HIV RNA copies/ml.  
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Darunavir is one of the recommended antivirals by the NIH Office of AIDS Research (OAR) for 
the treatment of HIV-1 [31]. It was originally patented in 2001 and approved by the FDA in 2006 as a 
second generation protease inhibitor, improving the potency and adverse side effects of first generation 
inhibitors [32]. Darunavir, [(1R,5S,6R)-2,8-dioxabicyclo[3.3.0]oct-6-yl] N-[(2S,3R)-4- [(4-
aminophenyl)sulfonyl- (2-methylpropyl)amino]-3-hydroxy-1-phenyl- butan-2-yl] carbamate), is an 
effective, highly potent nonpeptidic inhibitor that embeds itself into the protease active site via hydrogen 
bonds (Fig. 2.3). The structure allows more hydrogen bonds within the active site to be formed compared 
to other protease inhibitors [31]. 
 
 
 
 
 
 
 
 
Darunavir binds through hydrogen bonds to Asp 29 and Asp 30, successfully inhibiting HIV gag 
and gag-pol polyprotein cleavage. Binding at these sites attributes to its high potency [33].  In laboratory-
synthesized strains, darunavir had 50% effective concentration of 1-5 nmol/L. The addition of α1-acid 
glycoprotein (AAG) and human serum more accurately mimics in vivo and increased the IC50  20-fold. 
Darunavir is often administered with a boosting dose of ritonavir to increase drug effectiveness. Single 
Figure 2. 3: Darunavir Structure [2] 
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600 mg doses of darunavir have a bioavailability of about 37%, compared to 82% when administered 
with a 100 mg ritonavir.       
2.2.6   Combination Therapy 
HIV antiviral therapies are most commonly prescribed in combination in a highly active 
antiretroviral therapy (HAART) approach, referred to as the "Anti-HIV Cocktail" [12, 34]. 
Conceptualized in 1996, HAART has since significantly improved the prognosis and quality of life of 
HIV-infected patients. Modeled after tuberculosis treatment, three or more therapies are taken at once in 
order to produce a synergistic effect between different molecular targets, to lower the dose of each 
individual drug and decrease the probability of drug resistance. Tenofovir is the most commonly used 
antiviral in the United States, prescribed to 65% of patients on an antiviral regimen. The World Health 
Organization (WHO) launched the "3 by 5 Program", which was an initiative to get 3 million HIV 
infected patients on antiviral therapy by 2005, in response the effectiveness of HAART. 
In a study conducted by Finzi et al., 22 patients treated with HAART were successfully treated 
over the course of 30 months [34]. The patients involved in this study had T cell counts ranging from 0.2 
to 16 per 106 cells at the time combination therapy began. HIV-1 RNA levels were approximately 
undetectable 2 months after the HAART regimen was implemented (Fig. 2.4).  In the same time frame, 
the majority of patients exhibited a significant increase in CD4 cell counts. 
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Figure 2. 4: Effect of HAART Therapy on Plasma HIV-1 RNA and CD4 Cell Counts [34] 
 
Administered HAART therapies usually consist of three of four NRTIs and/or NNRTIs, one or 
more of three major drug classes, or a single PI with a boosting inhibitor [30]. Since HAART therapy is 
the future to HIV management, there are several drugs available on the market that are combinations of 
different inhibitors as one medication. One combination of three NRTIs is Trizivir, composed of abacavir, 
lamivudine and zidovudine. Approved in 2011, Complera is composed of 2 NRTIs and 1 NNRTI: 
emtricitabine, tenofovir disproxyl fumarate and rilpirivirine. The two newest FDA approved combination 
capsules are Evotaz and Prezcobiz, approved in January 2015 as protease inhibitors with a boosting 
inhibitor. Both use cobicistat to enhance the effectiveness of the inhibitor.  Evotaz contains atazanavir and 
Prezcobiz is made with darunavir. 
2.2.7   Therapy Limitations 
The primary limitation to HIV antiviral treatment is the many systemic and adverse side effects 
[35]. Since HAART therapy is widely used, common effects of several frequent high doses of medication 
is kidney stones and hepatotoxicity. The high doses of toxic drugs can often damage the liver and excess 
drug accumulates in the kidneys. Another side effect is a gastrointestinal reaction, such as nausea, 
vomiting and diarrhea, which is consistent with several medications. High levels of triglycerides, 
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cholesterol and blood glucose levels is another common systemic effect that can lead to fat redistribution, 
decreased bone density and bone marrow suppression. 
 Medical adherence is another drawback to current HIV antiviral cocktails [36]. Patients fail to 
take their medication as prescribed for a variety of reasons. Cost of medication is one of the most 
common reasons, as HAART therapy can cost $2000-$5000 monthly, and amount to over $500,000 in a 
lifetime. Because of cost and/or availability, lower doses of medication are sometimes taken in attempt to 
stretch supplies or are shared amongst families.   
Another factor that significantly affects therapy effectiveness is the resource availability and 
socioeconomic status of patients. A study conducted by Dabis et al. found that patients in low-income 
settings had lower CD4 cell counts and a higher instance of mortality when using HAART therapy than 
higher income countries [37]. One of the primary factors concluded to contributing to the higher mortality 
rate is the lack of follow up throughout the progression of treatment. Additionally, co-infections with 
other infectious pathogens, specifically mycobacteria, can have a significant impact on therapy 
effectiveness in poorer countries. Lastly, another main factor in therapy success in low-incomes is the free 
access to drugs and use of generic brands. Several countries in south and east Africa, including Botswana, 
Malawi and Uganda have restricted access to therapies.  
2.3   HIV-1 Protease 
HIV-1 protease is vital for the maturation of HIV after the virus buds from the host cell. This is 
one component of the life cycle that can be targeted and inhibiting therapies to limit the propagation of 
the virus throughout the body.  
2.3.1   Structure                                                                                                                     
HIV-1 viral protease is a relatively small protein that accounts for a pivotal role in the life cycle 
of HIV-1 [7]. In nature there are many forms of protease that utilize several types of catalytic mechanisms 
to cleave specific peptide bonds within a protein structure. Retroviral HIV-1 protease is a considered to be 
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a symmetrical homodimer that is composed of two identical dimers. Each of these small protease dimer 
subunits are made up of 99 amino acids. Modeling of HIV-1 protease mutants is much simpler than larger 
complex proteins since these dimers only consist of 99 amino acids. Each dimer has 18 β-strands and 2 α-
helixes that are oriented to create a structurally stable and highly functional enzyme. 
 HIV-1 protease has six major regions that play roles in the structural stability and catalytic 
properties of the enzyme [38]. The first region of importance for HIV-1 protease is known as the flap 
domains located on the most superior region of the enzyme. The flap domains for each dimer are formed 
by two anti-parallel β-strands composed of viral amino acids 44 through 57 [38]. The flap domains are 
highly mobile domains within HIV-1 protease that interact with viral gag-pol polyproteins to assist in 
peptide bond cleavage. These flap domains are able to move easily due to the elbow regions consisting of 
viral amino acids 49-52 that directly allow for the anti-parallel flaps to move about the elbow axis. The 
reason for the high amounts of mobility of the viral protease flap domains is the glycine rich regions with 
the elbow region. HIV-1 protease flap domains and elbow regions work together to ensure proper binding 
of the gag-pol substrate to the enzymatic active site. Scott et al. found that the relative static charges of 
the viral flaps and active site domains to the charge of the gag-pol substrate cause conformational changes 
in HIV-1 protease for proper substrate binding [39]. The active site within this enzyme is highly 
hydrophilic as a result of the catalytic properties present within this region. The flap domains of the 
enzyme have a hydrophobic surface that remains in a closed conformation when in contact with its 
external environment to maintain a neutral charge. However, the gag-pol polyprotein has a net positive 
charge, which wants to repel the positively charged flap domains of the viral protease causing the flaps to 
pivot about their glycine rich elbow regions. While the flap domains undergo the conformational change 
the net negative charge of the active site attracts the positively charged gag-pol substrate for proper 
binding. Through the use of molecular dynamic simulations of wild type and mutant variants of HIV-1 
protease it was discovered that glycine-51 in the elbow region found of the flap domain significantly 
affects viral protease activity. A mutation to glycine-51 can cause the flap domains to remain in a closed 
conformation when the gag-pol substrate tries to interact with the enzyme. 
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 The next two major domains of HIV-1 protease are the highly hydrophobic regions. These 
domains are located in the medial and inferior regions of viral proteases [40]. The first of these 
hydrophobic domains is the medial region composed of antiparallel β-strands, which play an important 
role in the stability of the homodimer. The inferior region of protease is composed of both β-strands and 
α-helixes that also contribute to the overall stability of the enzyme. These two hydrophobic regions are 
differentiated by what are known as the 10’s and 60’s loops. The 10’s loop is specific to the medial 
hydrophobic domain that consists of viral amino acids 15 through 18. Similarly, the 60’s loop is specific 
to the inferior hydrophobic domain, which consists of viral amino acids 66 through 69. Until recently it 
was thought that the hydrophobic domains of HIV-1 protease had little to no effect on the proper binding 
of the gag-pol substrate to the enzymatic active site. Hydrophobic sliding was observed when HIV-1 
protease wild type and hydrophobic mutants were simulated using molecular dynamics [41]. The Schiffer 
lab was able to determine that protease undergoes conformational changes within the hydrophobic 
domains of the protease through the “sliding” movement of the loop regions.  
 The final domains of HIV-1 proteases molecular structure responsible for functionality are the 
dimerization and active site regions [42, 43]. HIV-1 protease is an enzyme that is formed when the two 
identical dimer subunits fold into the proper form. The most important site of interaction between the two 
dimers during the protein folding process is the dimerization region. The dimerization region is where the 
four amino acid long N and C termini of both dimers orient themselves tightly together to form a 
functional enzyme. Arguably the most important region within HIV-1 protease is the active site. The 
active site is where HIV-1 protease performs the catalytic properties that the enzyme is known for. HIV-1 
proteases catalytic activity is due to two aspartic acid residues (Asp-25 and Asp-25’) which cleaves 
specific peptide bonds while creating by products typically seen in hydrolysis. 
2.3.2   HIV Virion Maturation 
As described earlier, the HIV-1 viral maturation process occurs after virions have budded out of 
the host cell. The immature virion consists of gag and gag-pol polyproteins that are inactive proteins. 
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These viral proteins become functional when the gag and gag-pol polyprotein complexes are cleaved at 
ten specific peptide bonds [44]. HIV-1 protease is also initially in an inactive form during virion budding 
since it is associated with the gag-pro-pol polyprotein. Once virion budding occurs, HIV-1 protease 
undergoes self-maturation where it cleaves itself from the gag-pro-pol polyprotein. The mechanism that 
HIV-1 protease performs to undergo self-maturation is still not understood.  
However, the functional form of the viral protease cleaves the polyproteins found within the 
virion to produce proteins required for HIV-1 survival known as MA, CA, NC, RT, and IN. The matrix 
(MA) protein plays a major role in pre-budding since it is responsible for aligning the gag and gag-pol 
polyproteins to the plasma membrane of the host cell [44, 45]. Once matured, MA proteins orient 
themselves directly under the virion plasma membrane. Capsid (CA) proteins are responsible for forming 
a stable shell within the virion to protect essential viral proteins for viral replication including NC, PR, 
RT, and IN. The capsid protein is thought to be another important protein associated with the HIV-1 life 
cycle since this particular protein has been observed to have the lowest amount mutations [45]. The 
nucleocapsid (NC) proteins are known to bind to viral RNA in order to successfully bring the viral RNA 
towards the center of the capsid during maturation. Reverse transcriptase (RT) protein is the protein that 
gives retroviruses the capability of converting viral RNA into viral DNA. Finally, integrase (IN) protein is 
an enzyme that HIV-1 used to integrate the viral DNA produced by RT into the host’s genome. 
2.4   Mechanisms of Drug Resistance 
One of the most important factors leading to antiviral therapy failure is viral resistance [46]. The 
key to improving viral inhibitors is understanding the mechanisms and factors that lead to drug resistant 
variants of HIV-1. 
2.4.1   Mutation Based Drug Resistance 
Of the roughly 25 different drugs used to suppress HIV-1 approved by the FDA, protease 
inhibitors are the most effective choice of inhibitors [7]. The efficiency of HIV-1 protease inhibitors is 
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partly due to the fact that the inhibition of the viral protease causes the essential proteins for viral 
replication to remain inactive. HIV-1 has been able form drug resistant variants for each type of inhibitor, 
however, protease inhibitors have the most mutants.  
HIV-1 drug resistance is not a static process, conversely, many factors contribute to viral drug 
resistance [8]. One important factor that contributes to HIV-1 drug resistance is the short life cycle of the 
retrovirus. Since the virus is short lived it has an extremely high rate of replication such that virions are 
produced daily. Also, HIV-1 does not have a proofreading mechanism for the RT protein so there is a 
high amount of random genetic variation between successive replications of the virus. The combination of 
high replication rates and error-prone transcription results in the evolution of HIV-1 strains in vivo. HIV-1 
can make random mutations that are useful for survival in the presence of an inhibiting drug and this 
particular strain will be selected for. Drug resistance can also be reached by means that are not related to 
the nature of HIV-1 [7]. The most common means of drug resistance if the failure to consistently take the 
anti-viral treatments prescribed.  
Successful drug resistant variants of HIV-1 protease are capable of exhibiting the catalytic 
functions of the enzyme through mechanisms slightly different from the wild type [7]. The tertiary 
structure of HIV-1 protease is directly dependent on the 99 amino acids found in each dimer and the way 
in which they fold. The inhibition of protease through protease inhibitors depends on the 
hydrophilic/hydrophobic interactions between the substrate and active site as well as the three 
dimensional orientation of both entities. Protease inhibitors are small molecules that mimic the three 
dimensional orientation of the substrate region that binds to the active site [47]. These protease inhibitors 
alter the functionality of HIV-1 protease by competing with the substrate for binding in the active site. 
The advantage of protease inhibitors is that they have a much higher affinity for the active site since they 
were designed to mimic the transitional state of the substrate. Drug resistant strains of HIV-1 protease can 
be developed through mutations within the active site. Functional active site variants can reduce the 
affinity of an inhibitor towards the active site and give the substrate a better chance at binding.  
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2.4.2   Substrate Shape Dependent Resistance 
Protease inhibitors are peptidomimetics, relying on structure based design targeting, opposed to 
site specific protein binding within the active site [46]. HIV protease is a resilient and adaptable 
homodimer that can bind to its substrate even without having properly oriented ligands. Prabu-Jeyabalan 
et al. identified crystal structures for six complexes that correspond to six of the ten gag and pol cleavage 
sites. It was concluded that viral protease recognizes the asymmetric shape of the substrate peptides 
instead of the specific amino acid sequence or set of hydrogen bonds. Protease inhibitors are successfully 
structured based designs. However, HIV mutates frequently and is error-prone to frameshift mutations, 
altering the active site. Therefore, marginal crystal structure changes of the protease substrate may confer 
drug resistance.  
2.5   Drug Resistance Simulation and Molecular Dynamics 
Drug resistance often occurs in sites of HIV-1 protease that experience the most movement, such 
as the flap regions [39]. Crystallization and sometimes NMR are unable to provide enough details on the 
role of individual atoms. These atomic details are often necessary to understand the substrate recognition 
process and why mutations on and around high movement regions lead to drug resistance. 
Hypotheses of atomic level movement of HIV-1 protease are often based on molecular dynamic 
simulations [39]. Simulations provide a dynamic viewpoint of several biomolecules and interactions 
between biomolecules [48] These simulations have become a standard tool for analyzing biomolecules 
and have been developed to use more realistic boundary conditions and longer simulation times. 
Molecular dynamics bring the dynamic movement data for biomolecules in solution, time-average 
molecular properties that are comparable to the experimental properties, and thermally accessible 
conformations. With that information, scientists can gather the movement of the biomolecule, free energy 
differences (ligand binding), and ligand-docking applications. 
2.5.1   Homology Modeling 
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Homology modeling is essential for creating structurally accurate models for proteins [49]. The 
model uses a protein structure prediction process via a computer program that includes template 
identification, alignment, and model building [50]. Template identification is finding a PDB (Protein Data 
Bank) file of a biomolecule from an amino acid sequence that the user created or edited. This edit could 
refer to a mutation of one of the amino acids of the sequence. The computer program provides several 
possible template identifications and the user chooses which PDB or structure best represents the desired 
biomolecule. The alignment stage pertains to aligning the entered amino acid sequence of the user to the 
amino acid sequence of the chosen template. Next, the 3-dimensional model of the user’s amino acid is 
built based off of the 3-D structure from the template [49].  Creating these models use the computer 
programs' structure prediction workflow, called a run, which uses particular templates, paths, and settings. 
The built structure can be manually modified if the prediction software did not provide the user’s desired 
structure. These “mistakes” are essential to get fixed because the misrepresentations can greatly affect the 
chemical/physical properties and therefore the movement of the protein. 
2.5.2   Molecular Dynamic Preparations 
After the model of the protein is developed, the protein must be refined, which is part of the 
preparation process for experimentally resolved protein structures used in calculations [49]. Refinement 
includes loop refinement, side-chain prediction, minimization, rigid-body minimization, hybrid Monte 
Carlo conformational searching, binding site refinement, and energy analysis based off of the structure’s 
geometry [50]. The refinement stage double-checks if the physical and chemical properties of certain 
aspects of the biomolecule are realistic. Specifically, the refinement tools can fix many structural 
problems, such as formal charges, bond orders, and disparities between the sequence and the structure. 
This type of correction was mentioned before in the homology modeling, but the software checks in case 
the user did not notice every structure problem. 
Many computer programs also provide solvation models for the biomolecule. Solvation models 
provide an environment for the biomolecule [50]. There are three common options for the solvation 
   23 
model. The first is VSGB that provides an aqueous model/ water environment. The vacuum option turns 
off the solvation model (no water) chloroform that uses the SGB method. The model also has boundary 
sizes to determine how large the user would like the environment for the biomolecule to be. Standard size 
for HIV-1 protease is a boundary size of 10 x 10 x 10 angstroms [39]. The refining loops capability 
checks the loop structure using different algorithms for various loop lengths [50]. The prediction of side 
chains capability estimates the conformation of the biomolecules’ side chains by sampling multiple 
orientations to obtain the one with the smallest energy (minimized energy). The side chains that are 
chosen for the sidechain minimization step are the mutated amino acids/residues. 
Minimization involves sampling different orientations of the biomolecule or parts of the 
biomolecule to find the lowest energy orientation [50]. There is an option to treat part of the system as a 
rigid body with freely moving atoms and freezing the rest of the system, which is known as rigid-body 
minimization. Rigid-body minimization is sometimes preferred because it is less time-consuming than 
minimization. The hybrid Monte Carlo process simulates the molecular dynamics of the biomolecule 
using high-temperature. This explores the conformational space of the biomolecule to obtain the lowest 
energy structure/orientation. The protein-ligand complexes can be used to refine the interactions between 
the protein and ligand by sampling positions and conformations of the ligand. This process is also known 
as binding site refinement. The last step of refinement is analyzing the molecular mechanics energy. The 
program uses an all-atom force field to predict the energies. These energies can be broken down to 
covalent, Coulombic, van der Waals, and solvation energy contributions. The energies can be broken 
down to certain sections of the biomolecule, such as residues, and visualized on the structure. 
2.5.3   Molecular Dynamic Simulation 
Once the preparation of the model is complete, it can run through a molecular dynamic simulation 
[39]. This simulation is run through a separate computer program with the necessary calculations to 
provide accurate movements of the protein. Specifically, the program takes in all the parameters, which 
include several constraints on how the atoms move, and the original atom coordinates. A time is selected 
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on how long the simulation of the protein is ran, which 100 nanoseconds is a common choice. The atom 
coordinates, based off of the constraints, are recorded after each time frame of the simulation. 
After the simulation is done, the computer program gives the information on the atom coordinates 
and their energy levels for each time frame, which is commonly 10,000 [51]. This information can be 
further analyzed to summarize the movement of the protein and/or to predict the interactive forces 
between or within the protein and inhibitor. 
2.5.4   Molecular Dynamic Analysis 
      One of these analyses is known as RMSF, or root-mean squared fluctuation. The equation for 
RMSF is shown below [52]: 
𝑅𝑀𝑆𝐹! = [1𝑇 𝑟! 𝑡!) − 𝑟!!"# !]!!!!!
!/!
 
 
The RMSF is the deviation between the position of atom I and some reference position [52]. The 
time point for the molecular dynamic simulation is denoted as j, the T is the total period of the molecular 
dynamic simulation, ri(t) is the position of the atom in that trajectory time point, and riref is the position of 
the atom from the reference time point, which is usually time zero. RMSF values represent the average 
movement of the atom over the entire simulation time.  When comparing the RMSF values of certain 
atoms or sections of the biomolecule, the values can show which sections are more flexible or experience 
movement more than others. 
There are several other analysis tools that VMD can calculate. For this project, the protein-ligand 
RMSD, protein RMSF, ligand RMSF, hydrogen bonding, and van der Waals values between the ligand 
and biomolecule. The equation for the RMSD is shown below [52]: 
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M is the sum of masses of the molecules being investigated; N is the number of atoms, m and the mass of 
the atom that is being investigated. The RMSD values for a biomolecule or usually calculated for the C-
alpha atoms because they are the most stable /backbone of the biomolecule [52]. The values of RMSD are 
compared among the C-alpha atoms (one pertaining to each residue of HIV-1 protease) and represent the 
total movement of the pertaining atom. 
Hydrogen bonding is whether the ligand and protein have potential to make hydrogen bonds 
during their interaction. This type of bonding gives an idea on whether the ligand will successfully attach 
and/or stay in the active site. The hydrogen bonding is defined by a certain distance between the two 
atoms, which is usually around 3 angstroms [52]. The van der Waals values are the attractive forces that 
keep the ligand attached to the active site. 
2.5.5 Molecular Dynamic Software 
Maestro: 
Maestro is a molecular visualization interactive computer program produced by the company 
Schrodinger [53]. When coupled with Prime, another Schrodinger program, the program can build a 
computer-generated model of a biomolecule with realistic environmental properties. Prime includes 
refinement, solvation models, and minimization. This model will later be ran through a molecular 
dynamic simulation to provide information on the atomic-level movements of the biomolecule. The 
program is user friendly and used mainly for building, visualizing, and sharing 3-dimensional chemical 
models. For more detail of the homology modeling and refinement criteria, see the Prime User Manual 
provided by Schrodinger [50]. 
Desmond: 
Desmond is the computer program that carries out molecular dynamic simulation [51]. This 
computer program is highly used among researchers because of its high accuracy and its effective 
computational abilities. Desmond is often considered the most accurate molecular dynamic simulation 
compared to other similar programs. 
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VMD: 
VMD is an interactive 3-dimensional molecular graphics program that is commonly used to 
analyze a biomolecule and its molecular dynamics simulation information, such as trajectories [54]. The 
program is able to take atomic coordinates, chemical and physical properties, and other information given 
by a PDB to provide an accurate graphical view of the biomolecule. The user can directly interact with 
the biomolecule by rotation, zooming in and out, and selecting certain atoms or sections of the 
biomolecule. Several features are included in VMD, such as coloring options, selecting options, graphical 
view options, and the ability to run additional analysis via external programming scripts. The ability to 
use external programming scripts allows the user to achieve further information about the biomolecule. 
For example, the trajectories of the atomic coordinates and their properties at several time points across 
the span of the molecular dynamic simulation can be used to display a 3-D graphical view of the 
movements of the proteins. The atomic coordinates of the different time points of the molecular dynamic 
simulation also gives the VMD to analyze the movements and interactions of sections of the biomolecule. 
These movements and interactions include RMSF (biomolecule and ligand), RMSD (biomolecule and 
ligand), hydrogen bonding, and van der Waals. 
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3.0 Project Strategy 
 The client Celia Schiffer, PhD, has an interest in "understanding the molecular basis of 
drug resistance and the ways the natural substrate specificity is maintained by the resistance viral variants 
[of HIV-1 protease]" [55]. However, HIV has been proven to be a highly error-prone virus that also has a 
high replication rate, leading to drug resistant variants. This project aims to understand the molecular 
basis of drug resistance common among affected patients. Further, the team will develop software 
programs to efficiently analyze aspects of drug resistance. 
3.1 Initial Client Statement 
 Initially, the client provided a statement for our team: 
 
Using Molecular Dynamic principles to analyze the effectiveness of the inhibitor on 
mutated variants of HIV-1 protease. Project goals are to include prediction of 
potential mutations of amino acid residues. 
 
After receiving the client statement, the team researched the current benchmarks of HIV-1 
protease therapeutics to gain a better understanding of the project. Through research, it was found that 
protease inhibitors are used as final stage antiretroviral therapy, where drug resistance has limited the 
effectiveness of initial therapies. Instead of focusing solely on protease inhibition, the team considered 
alternative mechanisms to prevent viral propagation within the body. These alternate considerations led to 
the development the following need statement: 
 
Develop a process to understand the mechanisms of drug resistance in HIV-1 protease, as it has a high 
degree of error-prone replication, in order to design more potent therapies to render the virus non 
functional regardless of present mutations. 
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The need statement entails the project's main goal and also allows the design space to be 
broadened. The engineering design processes can establish the best mechanism on how to address the 
need statement. 
3.2 Technical Requirements 
Lists of research and design objectives were developed based on the client need and after gaining 
a better understanding of the project. From ranked objectives, project constraints and functional needs 
were identified. 
3.2.1 Research Objectives 
These research objectives outline the necessary characteristics of an effective process to 
determine HIV-1 drug resistance mechanisms. Primary objectives include this research to be accurate, 
measurable, repeatable and reproducible. Research objectives were compiled into an objectives tree, and 
are described in further detail below (Fig. 3.1). 
 
Figure 3. 1: Research Objectives Tree 
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The first objective identified is accuracy. It is critical that models accurately reflect the actual 
molecular structure and behavior. If the viral models are not indicative of actual behaviors, data is invalid, 
as it would not properly depict the real time virus mechanisms. Protein folding, conserved/bonded waters 
and environmental factors further characterize accuracy. Protein folding is dependent upon the 
consistency of the amino acid sequences. Different sequences will result in different folding patterns that 
can lead to various quaternary structures. When modeling mutations, the folded protein structure must 
mimic in vivo conditions. Conserved/bonded waters play a role in inhibitor binding and must be 
accurately portrayed to simulate in vivo settings. Lastly, environmental factors including temperature, 
pressure and pH can affect inhibitor binding and functionality. 
Another objective stipulated is measurability. Various data must be measured from the research in 
order to analyze inhibitor effectiveness. Dynamic protein behavior, including movement, bond distances 
and energies must be able to be measured. Movement is an important factor in determining whether the 
substrate is available for binding. This movement must be able to be detected in order to quantify binding 
and inhibitor uptake abilities. Bond distances are directly related to the presence of hydrogen bonds. This 
is an important measurement to determine if the inhibitor is experiencing hydrogen bonding with the 
protease. Energy levels are directly reflective of the interactions between the inhibitor and the substrate. 
These interactions, van der Waals forces, are determined by measuring the change in energy of the system 
when an inhibitor is bound and unbound. Bond distances and energy levels contribute to the overall 
strength of inhibitor to protein binding.  
   Repeatability is another important objective that must be satisfied through this process. When 
conducting research to develop conclusions and correlations, multiple trials must be executed. Therefore, 
the process must be able to be repeated multiple times, garnering consistent results across replicates. 
     The final primary objective identified is reproducibility. This entire experiment must be able to be 
conducted again, even in a different laboratory setting. Results obtained through additional experiments 
following this process should still conclude consistent results. 
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In order to rank objectives in order of importance, the team created a pairwise comparison chart 
(Table 3.1). Objectives were ranked against each other using a number system of 0, 0.5 and 1. Objectives 
that are determined to be of greater importance was given a 1 and the other objective received a 0. Each 
objective received a 0.5 if they were determined to be of equal importance. 
 
Table 3. 1: Research Objectives Pairwise Comparison Chart 
Objective Accuracy Measurable Repeatability Reproducibility Score 
Accuracy — 0.5 1 0.5 2 
Measurable 0.5 — 1 1 2.5 
Repeatability 0 0 — 0.5 0.5 
Reproducibility 0.5 0.5 0.5 — 1.5 
 
Accuracy and measurable were deemed as equally important since accurate measurements a vital 
to this project. The measurements obtained will be used to quantify inhibitor effectiveness, and this must 
accurately portray in vivo conditions. Comparing accuracy and repeatability, accuracy was deemed more 
important as there will always be variation among replicates because of the dynamic protein behavior. 
The team determined accuracy and reproducibility are of equal importance, since both are required to 
draw correlations of the effect of mutations on inhibitor effectiveness. Measurability is considered more 
significant than repeatability since conclusions will be based off of measured data. Measurability is of 
greater importance than reproducibility since measurements over multiple experiments determine validity. 
Repeatability and reproducibility are considered equally important, as both are required in developing a 
valid process. 
Using the pairwise comparison results, the team ranked objectives from most significant to least 
significant (Table 3.2).  
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Table 3. 2: Ranked Research Objectives 
Ranking Primary Objectives 
1 Measurable 
2 Accuracy 
3 Reproducibility 
4 Repeatability 
 
3.2.2 Design Objectives 
In order to properly analyze research simulation results, a software program is to be designed 
primary and secondary objectives were defined. Primary design objectives include, accuracy, adaptability, 
and efficiency. Design objectives were compiled into an objectives tree, and are described in further detail 
below (Fig. 3.2). 
 
Figure 3. 2: Design Objectives Tree 
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     The first objective defined is accuracy, as it is crucial the program accurately analyzes the 
simulation data. Included in accuracy is proper atom ordering during analysis, as raw data is exported 
with a non-ordered ligand sequence and the first residue of chain B is at the end of the data set. 
     The second design objective is adaptability. The modification of the programs to account for 
different mutations and data files is critical. Analysis of several point mutations and replicates are 
required to understand the mechanisms of the drug resistance. Further, the program should be used for 
additional experiments to maintain consistent analysis and must be able to be adapted accordingly. 
Therefore, the program needs to account for multiple data files and expected to provide consistent results. 
The last design objective of the software programs is efficiency.  Efficiency is vital to the analysis 
of the research outcomes and the ability to draw conclusions from the analysis. Efficiency is further 
characterized by the time for the programs to run and the capability of presenting the data representation 
in a clear and concise fashion.  
     To rank objectives in order of importance, the team created a pairwise comparison chart (Table 
3.3). Objectives were ranked against each other in the same fashion as research objectives. 
     
Table 3. 3: Design Objectives Pairwise Comparison Chart 
Objective Accuracy Adaptability Efficiency Score 
Accuracy — 1 1 2 
Adaptability 0 — 0 0 
Efficiency 0 1 — 1 
 
Accuracy was ranked above adaptability, as the program must accurately account for 
discrepancies among data files. For similar reasons, efficiency was determined to be less importance than 
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accuracy. In the context of our project, efficiency is more important than adaptability, as data must be 
presented in a comprehensive manner with minimal script processing time.  
Using the pairwise comparison results, the team ranked objectives from most significant to least 
significant (Table 3.4). 
Table 3. 4: Ranked Design Objectives 
Ranking Primary Objectives 
1 Accuracy 
2 Efficiency 
3 Adaptability 
 
3.2.3 Project Constraints 
The team had to take into account multiple constraints based upon our client statement and 
design meetings with our project advisor, Celia Schiffer, PhD. The most important constraints that the 
team must take into account during the course of the project are: 
• In vivo environment 
• Minimum replicates 
• Time 
The first constraint of this project is the design must mimic the in vivo environment, including 
pH, temperature and pressure. The pH must be regulated, such that it remains near body pH, 7.4. In order 
to account for fluctuations within the modeling, the pH range is set to be 4.0 to 10.0 but is monitored 
throughout experimentation. Temperature is also an important factor in determining inhibitor 
effectiveness, since increased temperature increases molecular movement. In order to ensure accurate 
results, temperature must be 37°C and remain consistent throughout. Pressure must also remain consistent 
throughout experimentation, being conducted at one atmospheric pressure. 
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The second constraint of this project is the minimum number of replicates for each mutation. This 
project encompasses analysis from three protease mutations. Drug resistant patterns would be insufficient 
based off less than three replicates of each variant. 
Our final constraint is the timeline in place of the completion of the project. The project 
must be completed before Project Presentation Day during the 2016 school year. 
3.3 Industry Standards 
 
Industry standards for Molecular Dynamic (MD) simulations are fairly new and still developing. 
So far, there are requirements for the equilibration, boundary conditions, and the need for several MD 
runs [56]. For each MD simulation performed, equilibration must be reached. Equilibration can be 
detected by several factors, including root-mean squared displacement, or deviation, and steady 
temperature. The steady behavior of the root-mean square displacement of the protein and the steady 
temperature throughout the simulation will be observed. If neither are obtained in the particular 
simulation, the simulation is no longer valid for analysis. Boundary conditions are essential to an accurate 
simulation, as too large or too small directly impact the results. The boundaries are set to values of 
previous literature pertaining to our project, as they have tested different boundary sizes and found the 
optimal size. Lastly, the number of MD simulations for the same conditions are vital to an accurate 
analysis. MD runs are not quite accurate, but they are precise. Thus, several runs will give us enough 
values (mean value) to obtain accurate results. 
Another industry standard this project must adhere to are the standards and guidelines 
surrounding computer programming. MATLAB is one language with a published guide that specifies 
variable naming convention, the proper formulation and development of functions, organization of files, 
statements, and formatting [57]. This guideline will be considered when writing code for this project, as 
the team is designing a program that can be adapted for further analysis and potentially other proteins. 
Therefore, the code must be logical, well documented and commented, and formatted clearly for future 
edits to be made quickly.      
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 The final industry standard considered throughout the course of this project is ISO 18458:2015, 
regulating biomimetics [58]. This standard specifies regulations and definitions for computational 
analysis or systems that mimic a biochemical process. Recently developed, it provides a framework for 
biomimetic technologies and applications including scripting languages and programming resources.  
3.4 Revised Client Statement 
After the team gained a better understanding of the background and the broader need of 
the project, the team proposed a revised client statement. Discussions with the client further modified the 
team's revised client statement. Thus, the final revision was developed that both the team and client 
contributed to. 
 
Using molecular dynamic principles to analyze the effectiveness of the inhibitor on mutated HIV-1 
protease variants. Goals are to include finding potential resistance patterns to specific mutations, and 
discovering attributes for a drug that would be most effective to several mutations and possibly different 
classes of HIV. 
 
The revised statement added additional desired goals of the project. From literature and 
discussion, the team discovered that the most effective way to assess the need statement is to continue 
with the initial proposal but with further analysis. 
3.5 Project Approach 
In order to ensure project objectives are met within the given constraints, the team developed a 
project strategy broken down into a technical, management and financial approach.  
3.5.1 Technical Approach 
The team is considering using molecular dynamics to analyze inhibitor interactions, however will 
also develop alternative designs presented in chapter 4 using traditional “wet lab” analysis. After 
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determining the best form of analysis, mutations will be decided and data collected. From the data gained 
through experimentation, a software program will be written to effectively analyze and display results. 
Conclusions will be drawn to reach the project goal.   
3.5.2 Management Approach 
In order to complete the project within the specified time constraint, the team developed a Gantt 
chart to direct a course of action over the project timeline (refer to Appendix A). This chart breaks down 
each major project component into smaller tasks, to ensure milestones and deliverables are met. Task 
times were generously estimated to ensure the team adheres to the proposed timeline. Additionally, tasks 
and project work were front loaded to provide flexibility, should a research obstacle arise. To use time 
most effectively, certain team members were allocated and assigned to complete specific tasks. Tasks 
were assigned based upon the individual strengths each member added to the project group. In addition to 
the Gantt chart, the team created a project plan summary for each term (Fig. 3.2). 
 
Figure 3. 3: Project Management Plan by Term 
 
 
3.5.3 Financial Approach 
As with any design project, financial constraints must be taken into consideration. This 
will not be a limiting factor in our project, as the team will be conducting research and theoretical 
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design. Should the project require any financial support, the team will mostly rely on resources 
available in the Schiffer Laboratory at the University of Massachusetts Medical School. 
  
   38 
4.0 Design Process 
The preliminary developments of the project design are presented in this chapter. This includes a 
summary of design needs, functions and specifications. Additionally, the conceptual and alternative 
designs are explored and evaluated. 
4.1 Needs Analysis 
As the project evolved through meetings with the team and project sponsors, needs were 
identified and evaluated. We classified objectives to distinguish between functional needs that are 
required for the project and desirable needs that are not crucial to the design (Table 4.1).  
Table 4. 1: Project Needs Classification 
Functional Needs Desirable Needs 
Accuracy of simulation  Repeatability of simulation replicates 
Adaptable analysis for multiple mutations Measurable Alpha Carbon Distances 
Measurable RMSF, van der Waals 
interactions, and hydrogen bonding 
Comparison of different background 
environments 
 
The three most important objectives determined by the team are accuracy, adaptability, and 
measurability. Based off these objectives, the functional needs deemed necessary to the project design are 
that the simulation is an accurate portrayal of in vivo behavior, the software analysis program is adaptable 
for various mutations, and that Root-Mean-Squared Fluctuation (RMSF), van der Waal interactions and 
hydrogen bonds can be measured. 
The first functional requirement of the project design is the simulation must accurately depict in 
vivo conditions, including environmental parameters, protein conformation, and conserved and bonded 
waters. Accuracy of the simulation is imperative in analyzing the inhibitor effectiveness. Secondly, the 
analysis program must be designed to be adapted to various mutations beyond the three mutations the 
team is evaluating. Variants the program can analyze must range from single point mutations to a 
combination of n-point mutations and must be accurate and consistent across all scenarios. The final 
functional requirement requires the analysis program to be designed to include accurate measures of 
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protein movement and energy. This can specifically be defined as RMSD, RMSF for the protein and 
ligand, van der Waals interactions and hydrogen bond percentages.  
Repeatability, C-Alpha distance measurements, as well as comparing different background 
environments were categorized as desirable needs. Due to the dynamic nature of HIV-1 protease and flap 
movement, slight variations in replicate data, especially in protein and ligand RMSF data, are to be 
expected. However, accurate simulation setup can mitigate any large discrepancies between replicates 
making our design more consistent. 
Secondly, C-Alpha Distance measurements provide additional information about the protein and 
ligand behavior, although are not essential for the scope of our analysis. More pertinent information can 
be gained through examining RMSF, van der Waals and hydrogen bonds, which are of interest to our 
sponsor. Similar to C-Alpha Distance data, comparing mutation data across different backgrounds would 
be beneficial to observe any different inhibitor interactions.  
4.2 Conceptual Designs 
 To meet the project’s functional and desirable needs, the team will follow a set of steps to achieve 
the analysis of the HIV-1 protease mutations’ affect on the binding of the inhibitor. These steps are shown 
in Figure 4.1. 
Model the Mutations  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. 1: Conceptual Project Design 
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Firstly, the team will choose at least three different mutations to analyze and compare to wild 
type. To test the hypothesis of whether there is increased resistance conferred with increased mutations, 
we wanted to choose mutations that are compounded (following the pattern x, x+y, and x+y+z). Once the 
mutations are chosen, the team will determine a process to effectively gather large amounts of data. These 
data include time-dependent protein dynamic behavior and inhibitor interactions. An important 
consideration in developing this process is the number of replicates to achieve accurate and sufficient 
data. Lastly, the team will team will develop analysis programs to process the information collected. This 
is comprised of calculating certain measurements, including RMSD, RMSF, van der Waals, hydrogen 
bonds, and alpha carbon distances across the active site, and comparing those measurements to wild type 
and other mutation variants. These scripts will make this process more efficient and effective, and provide 
visual representations. 
4.3 Alternative Designs 
Since there are a variety of techniques to analyze protein functionality and interactions, there are 
several approaches the team is considering to approach our project problem. Conventional methods of 
protein analysis are facilitated through “wet” lab practices that give either direct or indirect information 
about the protein of interest. In vitro analyses that can detect protein functionality include protein 
purification and protein detecting. However, these practices are not specific enough to determine the 
finest details involved in drug resistance development since they are limited to detecting only the highest 
level of protein complexity (tertiary and quaternary structures).  
The recent growth of technology allowed for the use of computational analysis in protein 
analysis. Information can span from the quaternary structure down to individual atoms. Currently, 
computational analysis methods include protein structure prediction, protein sequence/structural 
alignment, and molecular dynamics. Each of these techniques provides valuable information about protein 
functionality, but molecular dynamics is the only method that provides real-time analysis of protein-
ligand interactions.  
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The team brainstormed a list of attributes that are necessary to our project and determined which 
method, computational or wet lab analysis would suit the project needs. These attributes are listed in 
Table 4.2 and the methods more suitable to meet each attribute are marked with an x. 
Table 4. 2: Comparison of Computational and Wet Lab Analysis 
Attributes Computational Analysis 
“Wet” Lab 
Analysis 
Subtle Specificity X 
 
Ideal Environmental Assumptions X 
 
Cost-Effectiveness X 
 
Amount of Data X 
 
 
There are many open-source and private molecular dynamic analysis software available for use. 
However, private software is normally the recommended since this analysis requires super-computers to 
conduct the massive amounts of computational analysis. Although, the team had accessibility to the 
Desmond molecular dynamic software additional software were researched such as Abalone, ADUN, 
Amber, COSMOS, CP2K, and Culgi. 
Within Schroedinger’s Maestro software are many selection parameters that need to be properly 
accounted for to obtain accurate data for our protein analysis. Firstly, the proper force field must be 
selected in order to subject our protein-ligand complex to mimic in vivo environments. These force fields 
can be broken up into classical, polarizable, reactive, and coarsed-grained. For the contexts of this 
analysis, the classical family of force fields was best suited due to its specific effects related to proteins. 
This family is further broken down into MMFF, CHARMM, Amber, and OPLS, which are all force fields 
specific to proteins and protein compositions. OPLS is only force field that incorporates the proper 
environment that accounts for proteins, small molecules, nucleic acid, and lipids.  Another important 
parameter to consider is the time span of simulation. Typically molecular dynamic simulations are 
conducted in the nanosecond range. A simulation that is too short can result in incomplete data collection 
while a simulation that is too long can provide a less accurate representation of events occurring during 
the simulation. The Schiffer Lab has found through trial and error, that 100 nanosecond simulation 
provides an adequate amount of time to provide accurate data. Additionally, the team had to decide on 
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whether to focus on active vs. non-active site mutations. It is well documented that mutations made 
within the protein's binding pocket have a higher probability of affecting inhibitor binding dynamics. 
However, mutations found outside of the active side can alter the overall tertiary structure of the protein 
during protein folding. Finally, these simulations can be run on either a CPU or a GPU. The major 
difference between the two is that simulations run on a GPU are 30-80% faster than a CPU. The use of a 
GPU for simulations is the most logical choice since time was a major constraint for this project's 
completion.         
In order to analyze the data from the molecular dynamic simulations, the team will write software 
scripts. Common languages utilized for biological analysis are python and C. Additionally, the team 
considered the use of MATLAB for the analysis process. A list of strengths and weakness for each 
programing language is shown below in table 4.3. 
 
Table 4. 3: Comparison of Programming Languages 
Programming 
Language 
Pros Cons 
Python • Easy to to Use 
• Modular (Biopython) 
• Able to Read PDBs 
• Modules are separate downloads 
• Difficulty handling large files 
C • C Library 
• Built in functions 
• No namespace 
• No run time checking 
• Team Unfamiliarity 
 
Matlab • Easy to to Use 
• Nice Visuals 
• Statistical Built-In Models 
• Visual Workspace 
 
• Difficulty importing PBD’s 
 
4.4 Final Design 
After evaluating design alternatives and comparing the benefits and limitations of each option, the 
team decided on the final design. The first design decision was to use molecular dynamics simulation 
software to observe inhibitor behavior and conferred drug resistance. Molecular dynamics (MD) was 
chosen, as it is the industry standard to compute time dependent behavior of molecular systems, and is 
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frequently used in the Schiffer laboratory. The key benefit of MD is it allows for the modeling of complex 
dynamic processes including protein stability and conformational changes. This will ensure the functional 
need of accuracy is met. From molecular dynamics, a study on drug interactions can be completed, 
meeting the project client statement of determining DRV effectiveness in the presence of various 
mutations. 
To conduct the MD simulations, the team chose to utilize Desmond. Desmond software analyzes 
models created by Maestro, an all-purpose molecular modeling environment manufactured by 
Schroedinger. In addition to having access to the Maestro software through the Schiffer laboratory, 
Schroedinger is a leading MD software providing advanced algorithms and customizable features. This 
allows for the protease amino acid residues to be replaced with the mutation of interest.   
When determining mutations to analyze, the team considered both active and non-active site 
mutations. Although shown to affect drug resistance, the mechanism by which non-active site mutations 
confer drug resistance is unknown. For this reason, the team chose to analyze active site mutations, which 
affects the conformation of the enzymatic binding pocket and impacts inhibitor binding. The chosen point 
mutations are: I84V, where residue 84, isoleucine, is replaced with valine for both chains, V82F+I84V, 
where valine is replaced with phenylalanine, and M46I+V82F+I84V, with methionine replaced with 
isoleucine. These mutations were found through previous in vitro viral passaging conducted by 
laboratories in collaboration with the Schiffer Lab.   
The final design decision the team made was the coding language used for the analysis program. 
For the majority of scripts, MATLAB was chosen because of its superior visual and graphing capabilities 
as well as its ability to import large data files. The resulting data files range in size from hundreds to 
thousands of data points, and the team decided MATLAB was the most capable and versatile program. 
The versatility of MATLAB would lend well to importing and reading various file types and sizes, while 
running at a fast speed. Further, the lab has MATLAB access and our design can be incorporated and 
supplement existing scripts that are across several coding languages. However, the team recognized the 
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limitation with MATLAB and decided to use python for one script to modify beta values in a PDB file in 
order to generate heat maps for visual analysis.  
    Once all design decisions were made, the team conducted a preliminary test of a single mutant variant 
that had previously been analyzed by the lab. The molecular dynamic simulation provided data consistent 
with past data, so the team continued with simulations and analysis of the I84V, V82F+I84V, and 
M46I+V82F+I84V variants.  
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5.0 Design Verification 
This chapter presents the results of each experiment performed modeling the HIV-1 protease wild 
type, mutant variants I84V, V82F+I84V, and M46I+ V82F+I84V. The results include protein RMSD, 
protein RMSF, ligand RMSF, alpha carbon distances, van der Waals interactions, and hydrogen bonds. 
5.1 Protein RMSD 
The protein root-mean-squared deviation (RMSD) was calculated for the 100 nanosecond 
simulation that was conducted for each replicate of each variant. RMSD analysis determines the extent of 
protein equilibration through molecular dynamic simulation.  This information is used to verify proper 
protein behavior during the simulation. Additionally, the moving average of the RMSD was calculated for 
each variant. Figure 5.1 shows the protein RMSD and their moving average for each replicate of each 
variant. The replicate data is shown in blue and the moving average in red. 
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Figure 5. 1: Protein RMSD replicates 1-3 of WT, I84V, V82F+I84V, and M46I+V82F+I84V 
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The average RMSD of the three replicates were calculated for each variant. The averages of the 
RMSD were then compared to wild type to observe any possible differences from the wild type 
simulations (Fig. 5.2). The replicate RMSD data is shown in blue and the moving average in red. 
 
A constant RMSD suggests an equilibrated (temperature, pressure, etc.) model of the protein. The 
jump to the constant position represents the equilibration process to the required temperature and 
environmental conditions. Overall, the average protein-ligand RMSD plots showed proper equilibration to 
Figure  5.  2:  Average  protein  RMSD  of  WT,  I84V,  V82F+I84V,  and  M46I+V82F+I84V 
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roughly 1.25 angstroms. Further protein analysis could be conducted since the protein's behavior 
appropriate. 
5.2 Protein RMSF 
The protein root-mean-squared fluctuation (RMSF) of each residue was calculated for each 
variant during their 100 nanosecond simulations. Protein RMSF describes the amount of fluctuation, or 
movement, of protein residues. Three replicates were conducted for each variant and the protein RMSF 
was calculated. 
The following plots show the protein RMSF for each mutation and wild type simulations (Fig 
5.3). The line graphs contain the replicate data with the red, green, and blue lines corresponding to 
Figure 5. 3: Protein RMSF Compilation of WT, I84V, V82F+I84V, and M46I+V82F+I84V 
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replicates 1, 2, and 3, respectively. 
The average RMSF values of the three replicates were calculated and graphed on a single graph. 
This was done to highlight any differences from the average mutant RMSF’s to wild type. HIV-1 wild 
type protease is depicted by the solid black line (Fig 5.4). Average protease variants I84V, V82F+I84V, 
and M46I+V82F+I84V are identified by red, blue, and green, respectively. 
 
 
     
The average protein RMSF compilation of each mutant and wild type showed notable differences. 
Firstly, the there were notable differences in fluctuation across each variant around residues 1, 99, and 
199. This is to be expected since this is the protein's dimerization region which is extremely motile. 
Overall RMSF values remained similar except for key regions such as the active site, flaps, and elbow 
regions. This line graph representation of protein RMSF makes it difficult to detect subtle changes 
between variants.    
Figure 5. 4: Average Protein RMSF values for WT, I84V, V82F+I84V, and M46I+V82F+I84V 
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The average protein RMSF values of each mutation were subtracted from the wild type averages 
to observe fluctuations caused by each mutation. This data was displayed in a bar plot format to improve 
visualization of the data fluctuation. Additionally, the average protein RMSF differences were split into 
separate plots for chain A and B to increase the visual size allowing for easier detection of significant 
changes. Protease variant differences of I84V, V82F+I84V, and M46I+V82F+I84V are identified by red, 
blue, and green, respectively (Fig. 5.5).    
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 Figure 5. 5: Differences Compared to WT protein RMSF 
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In the case of protein RMSF differences, several residues exhibit subtle differences to the wild 
type that can be considered negligible. To account for this, an additional plot showing the significant 
differences was created. Significant differences are shown below, defined as the difference from the wild 
type value at each residue is larger than the standard deviation of three wild type values at that residue 
(Fig. 5.6).    
 
The most significant fluctuations for each variant occurred around the dimerization region 
(residue 99). V82F+I84V also displayed significant differences around residues 19, 40, 55,118,142,and 
175. This variant had the greatest amount of variation when compared to wild type.  
Additionally, protein RMSF differences to wild type were also displayed in the form of heat 
maps, generated using PyMol. These heat maps display the protein structure as a cartoon ribbon. Dark 
blue shading displays residues with the least fluctuation, greatest stability, and span to red representing 
residues of highest fluctuations, least stability. Figure 5.7 depicts the protease protein colored by RMSF 
Figure 5. 6:  Significant Differences Compared to WT Protein RMSF 
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values ranging from -0.3643 to 0.7060 compared to Figure 5.8, which shows the RMSF difference to wild 
type with difference values ranging from 0.2506 to 2.1776. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Protein RMSF heat maps in figure 5.7 displays the information shown in Figure 5.4 with respect 
to the protein's structure. RMSF values of each residue were visually displayed in their correct protein 
primary structure. Additionally, a color scale was correlated to these RMSF values to display fluctuation 
in terms of a color. This display allows for a 3-D representation of the protein capable of visualizing 
regions of fluctuation.  
Key structural and functional regions of the protease were colored blue, indicating the most stable 
(Fig. 5.7). Specifically the alpha helices and the active site for each variant exhibited the highest stability. 
Regions of moderate to high fluctuation throughout the simulation included the flaps and 60’s loop 
Figure 5. 7: Protein RMSF Heat Maps for I84V (top left), V82F+I84V (top right), and M46I+V82F+I84V (bottom) 
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regions. I84V and M46I+V82F+I84V variants displayed small amounts of green and a significant amount 
of yellow and red. However, V82F+I84V just showed moderate fluctuation in the 60’s loop being strictly 
green. I84V and V82F+I84V variants displayed moderate fluctuation within the elbow regions, shown as 
yellow. The M46I+V82F+I84V variant showed an increase in fluctuation since it was orange.              
     
 
 
Similarly, Figure 5.8 displays protein RMSF differences compared to wild type on the protein 
structure. These representations allow for easier differentiation of fluctuation significance between 
variants to be observed. Regions in green represent the most conserved areas with fluctuation consistent 
with wild type. I84V and V82F+I84V variants had very similar color gradients with the V82F+I84V 
variant having slightly more yellow identifying slight increases in fluctuation compared to wild type. 
However, the M46I+V82F+I84V variant displayed a great amount of fluctuation compared to wild type. 
Figure 5. 8: Protein RMSF Differences Compared to WT Heat Maps for I84V (top left), V82F+I84V (top right), and 
M46I+V82F+I84V (bottom) 
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The active site showed moderate (yellow) fluctuation compared to both I84V and V82F+I84V (green). 
Also, the M46I+V82F+I84V variant displayed less fluctuation (light blue) compared to both I84V and 
V82F+I84V (green) in the 60’s loop region. Finally, the most significant fluctuation occurred in the tip of 
the flaps (red) compared to both I84V and V82F+I84V (green/yellow).    
5.3 Ligand RMSF 
 
The ligand root-mean-squared fluctuation (RMSF) of each residue was calculated for each variant 
during 100 nanosecond simulations. Ligand RMSF describes the amount of fluctuation, or movement, of 
ligand atoms. Three replicates were executed for each variant and the ligand RMSF was calculated for 
each one. The following plots show the ligand RMSF for each mutation and wild type simulations. The 
line graphs contain the replicate data with the red, green, and blue lines corresponding to replicates 1, 2, 
and 3, respectively (Fig. 9). 
Figure 5. 9: Ligand RMSF Compilation of WT, I84V, V82F+I84V, and M46I+V82F+I84V 
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 The average RMSF values of the three replicates were calculated and graphed on a single graph. 
This was done to highlight any differences from the average mutant RMSF’s to wild type. The ligand 
wild type is depicted by the solid black line (Fig 5.10). Average ligand variants I84V, V82F+I84V, and 
M46I+V82F+I84V are identified by red, blue, and green, respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 The average ligand RMSF compilation of each mutant and wild type showed limited differences. 
The line graphs for average wild type, I84V, and V82F+I84V ligand RMSF were similar. Each of these 
graphs followed the same trends with slight variations from wild type near residues 26, 28, and 35. 
However, the M46I+V82F+I84V variant follows a similar trend with substantially more significant 
differences around resides 7, 11, 13, 17, and 31-38.     
 
Figure 5. 10: Ligand RMSF Compilation of WT, I84V, V82F+I84V, and M46I+V82F+I84V 
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The average ligand RMSF values of each mutation were subtracted from the wild type averages 
to observe fluctuations caused by each mutation. This data was displayed in a bar plot format to improve 
visualization the fluctuation data. Ligand mutant variant differences I84V, V82F+I84V, and 
M46I+V82F+I84V are identified by red, blue, and green, respectively (Fig. 5.11).  
 
In the case of ligand RMSF differences, 
several residues exhibit subtle differences to the 
wild type that can be considered negligible. To 
account for this, an additional plot showing the 
significant differences was created. Significant 
differences are shown below, where the difference 
from the wild type value at each residue is larger 
than the standard deviation of three wild type 
values at that residue (Fig. 5.12).    
 
Figure 5. 11: Ligand RMSF Differences Compared to WT for  
I84V, V82F+I84V, and M46I+V82F+I84V 
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The significant ligand RMSF differences to wild type bar plot provided a better visualization of 
this analysis. Similar to Figure 5.11, the M46I+V82F+I84V variant clearly displays the most fluctuation. 
This is observed mostly in atoms 32 through 38, corresponding to the benzene ring. There was minimal 
fluctuation observed in the cyclopentadiene region, with the only significant change in RMSF occurring 
in atoms 25 and 26 when complexed to V82F+I84V. 
5.4 Alpha Carbon Distances 
Distances between the alpha-carbons (C-Alpha) of residues across the active site were recorded 
during the 100 nanosecond simulation for each HIV-1 protease variant. These distances determine the 
relative size of the active site and give insight on the dynamic movement of the protease. The residues of 
interest were 25-25’, 84-84’, 25-50, 25-50’, 25’-50, and 25’-50’, shown as red lines in the Figure 5.13 
below. The apostrophe following residue values signifies chain B residues and the red lines indicate the 
initial position of these alpha carbon pairings.  
Figure 5. 12: Significant Ligand RMSF Differences Compared to WT for I84V, V82F+I84V, and M46I+V82F+I84V 
   59 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 The C-alpha distances of WT for each replicate are shown in Figure 5.14. The distances of the 
first row are between 25-25’, 84-84’, 25-50 (left to right) and the second row are between 25-50’, 25’-50’, 
and 25’-50 (left to right). Replicate 1 is shown in blue, Replicate 2 is shown in red, and Replicate 3 is 
shown in yellow. 
 
Figure 5. 13:  Alpha Carbon HIV-1 Protease Wild Type Distances 
Figure 5. 14: Wild Type Alpha Carbon Distances  
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The C-alpha distances for I84V, V82F+I84V, and M46I+V82F+I84V were also calculated for each 
replicate (Fig. 5.15, Fig. 5.16, and Fig 5.17). 
 
 
 
Figure 5. 15: I84V Alpha Carbon Distances  
Figure  5.  16:  V82F+I84V  Alpha  Carbon  Distances   
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 For each variant, the C-alpha distances were consistent between each of the replicates. The 
average of each variant was calculated and put compared to Wild Type to see any differences in patterns. 
The averages of each variant are shown in Figure 5.18. Wild Type is shown in blue, I84V is shown in red, 
V82F+I84V is shown in yellow, and M46I+V82F+I84V is shown in purple. 
Figure 5. 17:  M46I+V82F+I84V Alpha Carbon Distances  
Figure 5. 18: Average Alpha Carbon Distances 
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The I84V variant alpha-carbon distances showed the most deviance from the wild type’s 
distances. The distance was smaller from wild type in all residues except for 25-50, which was a similar 
distance, and 25’-50, which was a larger distance. V82F+I84V had similar alpha carbon differences to 
wild type for residues 25-25’, 25-50, 25-50’, and 25’-50. Smaller distances were seen between 84-84’ and 
25’-50’. The M46I+V82F+I84V variant has alpha carbon distances similar to wild type for residues 25-
25’, 84-84’, 25-50, and 25’-50’. Distances between residues 25’-50 and 25-50’ for the M46I+V82F+I84V 
variant were smaller than wild type. Overall, there were no significant differences or patterns seen 
between the C-alpha Distances of the mutation variants compared to the wild type variants.  
Another way to visualize the alpha-carbon distances of the mutated variants were color coding the 
lines between the residues, of which the distances were measured. The colors corresponded to the average 
distance being larger, the same, or smaller than wild type. A red line represents a higher average C-alpha 
distance, a green line represents the same average C-alpha distance, and a blue line represents a lower 
average C-alpha distance to wild type. The C-alpha distances of the I84V variant is shown in the figure 
below (Fig. 5.19). 
 
 
Figure 5. 19: I84V C-alpha Distances Compared to WT 
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The C-alpha distances between residues 25-25’, 84-84’, 25-50’, and 25’-50’ are represented by a 
blue line, 25-50 by a green line, and 25’-50 by a red line. The C-alpha distances of the I84V variant are 
mostly smaller than wild type. Only one distance is similar to wild type and another distance larger than 
wild type. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 V82F+I84V C-alpha results were also compared to the wild type. The C-alpha distances between 
residues 84-84’ and 25’-50’ are represented by a blue line, while 25-25’, 25-50, 25-50’, and 25’-50 are 
represented by a green line. Generally, the average C-alpha distances of V82F+I84V variant were similar 
to wild type. Only two C-alpha distances had a lower average than wild type.  
 
 
Figure 5. 20: V82F+I84V C-Alpha Distances Compared to WT 
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M46I+V82F+I84V C-alpha distance between residues 25-50 is represented by a blue line, 25-25’, 
84-84’, 25-50, and 25’-50’by a green line, and 25’-50 by a red line. Most of the C-alpha distances of the 
M46I+V82F+I84V variant were similar to wild type. There was one C-alpha distances for both a larger 
distance than wild type and smaller distance than wild type.  
All the mutated variants experienced a smaller active site compared to Wild Type. The larger 
averages were seen between residues 25’-50. The C-alpha distances of the M46I+V82F+I84V variant and 
the V82F+I84V variant are similar to wild type, while the I84V C-alpha distances were smaller compared 
to wild type. 
5.5 Van der Waals  
 The van der Waals interactions between the ligand and the protein were calculated for each 
variant of HIV-1 protease. The following figures show the van der Waal interactions for each replicate of 
each variant. The interactions are divided into chain A and chain B residues for visual purposes (Fig. 5.22 
and Fig. 5.23, respectively). 
Figure 5. 21: M46I+V82F+I84V C-alpha Distances Compared to WT 
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  Figure 5. 22: Chain A van der Waals Energies for WT, I84V, V82F+I84V, and M46I+V82F+I84V 
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Figure 5. 23: Chain B van der Waals Energies for WT, I84V, V82F+I84V, and M46I+V82F+I84V 
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Each variant follows a similar trend across all replicates. Residues 25-31 generally had the 
greatest interactions with the inhibitor, with the exception of I84V chain B and V82F+I84V chain B. 
Although following a similar trend, residues 28 and 29 in chain A of wild type, I84V, V82F+I84V have 
energies of approximately -3.25 kcal/mol, compared to M46I+V82F+I84V with -2.75 kcal/mol. 
M46I+V82F+I84V chain A also had a lower energy at residue 60 with approximately -2.75 kcal/mol, 
compared to -2.25 to -2.5 kcal/mol seen in the other variants. With respect to chain B, wild type and 
V82F+I84V had the lowest energy at residue 60, approximately -1.75 and -1.8, respectively. Further, in 
the chain B variants there is a visible van der Waals interaction at residue 9 ranging from about -0.75 to -
1.25 kcal/mol. 
The average of the van der Waals energies of each variant were calculated. Similar to RMSF data, 
several residues had negligible Van der Waals interactions differences. The team determined through 
discussion with our sponsor that a difference greater than 0.02 kcal/mol was significant and is shown 
below for each residue. In these figures, chain A and chain B are both displayed on one graph (Fig. 5.24). 
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Figure 5. 24: Significant Average van der Waal Energies for WT, I84V, V82F, and M46I+V82F+I84V 
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Comparing the van der Waals interactions less than -0.02 kcal/mol with chain A and chain B 
plotted on the same graph, chain A generally had greater interactions than chain B. Especially at residues 
28 and 29, the average energy is significantly greater in chain A, and in the case of I84V and 
M46I+V82F+I84V is more than doubled.  
 
    Next, the average of the mutated variants’ van der Waals energies were compared to the Wild Type’s 
van der Waals energies. To provide a clearer portrayal of the significant difference data, residues with a 
difference less than 0.02 kcal/mol were removed and all three residues were plotted in the two figures 
below, which one is chain A and the other is chain B (Fig 5.25). 
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The van der Waals energies of all the residues were added together for each variant, including the 
mutated variants and wild type, to compare the total energy between the ligand and the protein. Wild 
Type had the largest van der Waals energies -34.2 +/- 2.2 kcal/mol. V82F+I84V and M46I+V82F+I84V 
were next with average van der Waals energies of -32.2. +/- 1.2 kcal/mol.  Lastly, I84V had an average of 
-30.6 +/- 0.9.  
Figure 5. 25: Significant van der Waals Difference to WT 
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5.6 Hydrogen Bonds 
 The hydrogen bonds between the protein and the ligand were calculated for every 10 picoseconds 
over the 100 nanosecond simulation. The percentage of time that each hydrogen bond was present 
throughout the simulation was determined. The average of the hydrogen bond percentages for each 
variant was compared to the wild type. These average hydrogen bond percentages are displayed in Table 
5.1 and shaded according to percentage. Additionally, the hydrogen bond percentages were added 
together to achieve total amount of hydrogen bonds for each variant during the simulation. 
 
 
 
 
 
 
 
 
 
 
 
Significant differences of the hydrogen bonds seen in Table 5.6.1 include the catalytic residue of 
chain A, which is residue 25 A to ligand atom number 18. I84V drastically decreases the occurrence of 
that hydrogen bonds while V82F+I84V and M46I+V82F+I84V drastically increase the occurrence of that 
hydrogen bonds. Another significant difference is the decrease seen between residue 29 in chain A and 
ligand number 28 of the M46I+V82F+I84V variant. The hydrogen bond occurrence of residue 30 of chain 
A and ligand number 26 decreases with the addition of mutations. The hydrogen bond percentage for 
residue 50 of chain B increases with I84V but decreases with V82F+I84V and M46I+V82F+I84V. 
 
Table  5.  1:    Average  Hydrogen  Bond  Percentages  of  WT,  I84V,  V82F+I84V,  and  M46I+V82F+I84V 
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Lastly, the sum of the percentages show that the mutations overall decrease the number of 
hydrogen bonds between the ligand and the protein throughout the simulation. They also show that 
M46I+V82F+I84V has the least amount of hydrogen bonds with I84V having a similar decrease in 
hydrogen bond percentages. However, V82F+I84V has a similar hydrogen bond character as the wild 
type. 
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6.0 Final Design and Validation 
6.1 Experimental Process 
     Molecular dynamic simulations were chosen as the experimental method to compute the 
structural dynamics and patterns of resistance to Darunavir (DRV) in mutant HIV-1 variants. The steps 
considered when running molecular dynamic (MD) simulations using Schroedinger’s Maestro are 
outlined in Figure 6.1.  
 
 
Figure 6. 1: Steps of Molecular Dynamics Simulation 
 
 
6.1.1 Preparation 
Preparation involves importing the protein’s information into the modeling software, modifying 
the model with the desired mutations, and adding virtual experimental conditions to the model. The 
modeling software used for the preparation step was Schrodinger’s Maestro. The methodology followed 
during the preparation step to build the homology model is as follows: 
1. Under the tasks tab, select homology model. 
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2. Click add files and import the genetic code sequence in the form of a PDB. 
3. Click next followed by blast homology search. 
4. Select and modify amino acid residues of interest in the genome sequence. 
5. Slide chain B residue 1 to the right until it is properly aligned following chain A. 
6. Click next. 
7. Select energy-based and homo-multimer check boxes. 
8. Select the inhibitor from the list, where DRV is denoted by 017. 
9. Click options, and select preserve residue number.  
10. Click build model. 
Completion of the above steps created a homology model of each desired mutation. However, this 
model is missing chain B residue 1, but it will be added and bonded to the protein during minimization. A 
PDB file of the HIV-1 protease DRV complex was imported instead of simply typing in a fasta sequence 
to provide the program with atom coordinates. The atom coordinates used in the preparation step directly 
impact the protein conformation and interactions observed from running the simulation. The PDB used 
was obtained from Research Collaboratory for Structural Bioinformatics (RCSB) protein data bank, an 
industry standard database, which will ensure the accuracy of the protein crystal structure. A homology 
model was created for each of our mutations of interest: I84V, V82F+I84V, and M46I+V82F+I84. In 
addition to modifying the amino acid residues for each mutation, a homology model without any 
mutations was generated to serve as the wild type control.  
6.1.2 Minimization 
     After generating the homology model, it is then processed using Maestro’s protein preparation 
wizard to change certain residues into their most minimized state, or the position requiring the least 
energy. This process also includes adding water molecules that are present in in vivo scenarios. Lastly, 
minimization ensures there are no clashing molecules, such as an overlapping water molecules. 
Minimization occurs through the following steps:   
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1. Under the tasks tab, select protein refinement, and click minimize. 
2. Change the force field to OPLS_2005. 
3. Under atoms, click the plus sign and then select. 
4. Under the sequence tab: 
a. Click chain A, sequence number and add 
b. Click chain B, sequence number and add 
c. On the left of the sequence tab, click backbone/side chain 
d. Select side chain and click intersect 
e. Click run.  
5. Import the original PDB.  
6. Delete all but chain B residue 1 by selecting the delete icon, select residue, invert, ok. 
7. Click the pencil icon and draw the bond connecting chain B residue 1 to 2. 
8. Import WT PDB to add crystallographic waters. 
9. Delete all molecules except waters by selecting the delete icon, click molecule, molecular type, 
water, invert, ok. 
10. Merge the water only model and the protein homology model. 
11. Check inhibitor bond orders and stereochemistry. 
12. Open the protein preparation wizard. 
13. Under the pre-process protein tab, check off: 
 a.   Assign bond orders 
 b.   Remove original hydrogens 
 c.   Convert selenomethionines to methionines 
 d.   Create zero-order bonds to metals 
 e.   Fill in missing side chains using prime. 
14. Under the pre-process protein tab, uncheck: 
        a.   Create disulfide bonds 
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      b.   Delete waters. 
15. Click pre-process. 
16. Click view problems. If there are overlapping atoms, delete the interfering waters atom(s) and 
click update. 
17. Under the review and modify tab: 
                a.   Click analyze workspace 
                     b.   Click generate states and select the lowest energy state. 
       18. On the refine tab: 
         a.   Under H-Bond assignment, click sample water orientations, minimize hydrogens of  
    altered species, click PROPKA and pH of 7.0 and click optimize. 
   b.   Under restrained minimization, select hydrogens only and click minimize 
    c.   Check problems, reports and plots 
      d.   Check Asp25 and note which chain is protonated. 
 
     Completion of the above steps successfully minimized the homology model created during 
preparation. The final step in minimization prior to simulation is creating an orthorhombic water box. 
This box has dimensions of 10x10x10 angstroms, contains no additional salt buffers and is neutralized. 
Prior to simulation, hydrogen atoms are also deleted from the model. 
6.1.3 Simulate  
After using Maestro’s protein preparation wizard, the system is ready for the simulation process 
using Desmond. The system is sent to a computer with the Desmond molecular dynamics script to run the 
simulation process. The time of the simulation and the type of computer you run the simulation on is 
specified in the submission of the Desmond job. The team chose 100 nanoseconds for the simulation time 
and GPU computers to run the simulation on.  
 To submit the simulation, the team followed these instructions: 
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1. Open a new terminal tab and enter the UMASS cluster. 
2. Go into the desired project folder and make a new folder for the specific simulation. 
3. Go back to the original terminal tab and go into the folder with the Desmond_setup_out file 
4. Transfer the Desmond_setup_out file into the new folder of the UMASS cluster with the 
command scp 
5. Copy the molecular dynamics protocol into the new folder of the UMASS cluster with the 
command cp 
6. Submit the job into the cluster with the Schrödinger submit command 
After the simulation is submitted, the Desmond script “heats” the system until equilibration at 
300 K. Once equilibration is reached, the system continues with the simulation. The simulation process 
involves applying an energy force field and environmental parameters to the system and recording the 
atoms’ coordinates and energies. These coordinates are the movement of the protein. The energies can be 
analyzed further to describe how well DRV was attached in the active site. 
The coordinates and energies are recorded for the 100 ns in a file. This file’s information can be 
analyzed to determine the RMSF, RMSD, hydrogen bonds, van der Waals, alpha-carbon distances, and 
much more of the protein and DRV. The team had three different simulations of each mutation and the 
wild type variant. 
Once the simulations were finished, the information was analyzed using Schrodinger’s Maestro, 
VMD scripts, and GFortran scripts. For Schrodinger’s Maestro, the protein interactions tool was utilized. 
This tool gave the protein RMSF, protein RMSD, ligand RMSF, hydrogen Bonds, and alpha-carbon 
Distances. VMD and GFortran was used to analyze the van der Waals of the ligand to protein. 
 
6.2 Data Analysis Process 
    The second component of the final project design is the analysis process and developed software. With 
the exception of the one python script to overwrite a PBD file, all scripting was conducted in MATLAB. 
This section contains highlights of the code written, and fully published code can be found in appendix B. 
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6.2.1 Protein-Ligand RMSD  
     A script for protein root-mean-squared deviation (RMSD) was written to initialize comma 
delimited value files. RMSD indicates the fluctuation of the alpha-carbon atoms (backbone of the protein) 
during the simulation. A higher RMSD indicates less protein stability. The program inputs comma 
delimited value files with a .csv file extension for each mutation, reads the data, and appends each RMSD 
value to an array. Additionally, the moving average for the entire protein RMSD was calculated using 
MATLAB’s built-in “tsmovavg” function (Fig. 6.2 line 144-146). The major component of this script is 
the graphical representation of protein RMSD (line 148-164). For each mutation replicate a line graph is 
generated with each of the three replicate data as well as an average. The moving average was then over 
laid on the graph. 
 
 
 
Figure 6. 2: Portion of RMSD Script 
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6.2.2 Protein RMSF  
     A script for protein root-mean-squared fluctuation (RMSF) was created to analyze the proteins 
movement during the simulation. The program utilizes text files generated from the molecular modeling 
software by reading the data and appending each RMSF value into an array. This script was created to 
help quantify the data collected during simulations into a graphical visual.  For each mutation a line graph 
is generated with each of the three replicate data. Additionally, a line graph is generated displaying 
average RMSF mutation replicates against wild type RMSF replicates. 
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Figure 6. 3: Portion of Protein RMSF 
 
 
 The RMSF values of each variant were then compared to the wild type. The average data set for 
each mutation was subtracted from the average wild type data set and appended into a new array (Fig. 6.3 
line 150-154). If the mutant had a larger fluctuation this difference would be positive and in the case there 
was less movement in the mutant ligand this value would be negative. This refined RMSF difference data 
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was plotted on a bar plot. Also, bar plots with a numerical threshold were coded to display significant 
fluctuations as shown in Figure 6.4. 
  
Figure 6. 4: Significant Protein RMSF Differences 
 
 
6.2.3 Ligand RMSF 
A script for ligand root-mean-squared fluctuation (RMSF) was written that initializes the text 
files output from the simulation. The program inputs the text file with a .txt file extension for each 
mutation, reads the data, and appends each RMSF value to an array. In the cases of mutant variants, the 
ligand atom numbers are not in proper order (Fig. 6.5). The correct ligand order was obtained from the 
PDB, which states the correct atom number of each element in the inhibitor. 
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To correct for this, the script properly orders the RMSF values of the three mutant variants using 
the sort function and appends to a new, properly ordered 3 x 38 array with each mutation as a column 
(Fig.  6.6). Similar code was written for each mutant variant and wild type. However, in the case of the 
wild type, the ligand is properly ordered. Therefore, the wild type portion of the code is similar but omits 
lines 20 through 24. As seen below, variable names were kept vague, such as Mut1_Rep1 or y1, to allow 
the script to be used for future analysis without requiring major editing.  
 
Figure 6. 5: Mis Ordered (left) and Properly Ordered (right) Ligand 
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Figure 6. 6: Ligand RMSF Data Import, Sort, and Plot 
 
 
    A major component of this script is the graphical representation of ligand RMSF. For each mutation a 
line graph is generated with each of the three replicate data as well as an average (Fig. 6.6, lines 27-34). 
To provide additional data representation, a subplot of the four line graphs was also generated. A final 
line graph is generated displaying average of each mutation and wild type RMSF (Fig. 6.7). 
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Figure 6. 7: Ligand RMSF Replicate Subplot and Average Plot Code 
 
      
 The RMSF values of each variant were then compared to the wild type. The average data set for 
each mutation was subtracted from the average wild type data set and appended into a new array (Fig. 
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6.8). In this case, the wild type average RMSF data is in the first column of if the matrix “Avg”. If mutant 
had a larger fluctuation this difference would be positive and in the case there was less movement in the 
mutant ligand this value would be negative. The standard deviations of the mutant variants were also 
calculated and appended into a matrix of standard deviation values. Lastly, code was written to generate a 
bar plot ligand RMSF differences compared to wild type.  
 
  
Figure 6. 8: Ligand RMSF Differences to WT Calculation and Bar Plot 
 
      
 Through discussion with the sponsor, the team determined some differences in RMSF values to 
be insignificant. Significant differences are defined as an absolute difference value that is greater than the 
standard deviation of the three wild type replicate data points for each residue. This was determined 
through a for loop where pre-allocated vectors of zeros remained a zero value if the RMSF difference was 
between the negative and positive wild type standard deviation for each residue (Fig. 6.9). If the 
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difference was outside these bounds, then the zero place holder would be changed to the RMSF 
difference.  
 
  
Figure 6. 9: Determining Significant Ligand RMSF 
 
      
 Since some values were left as a zero in the “statsig” array, an additional for loop was written to 
remove the condition of a zero (Fig. 6.10). This for loop appends to a new array if at least one of the 
mutations has a difference that is not equal to zero. If all three mutation RMSF differences are 0 in the 
“statsig” array, this for loop moves on to the next atom until reaching 38 atoms. The new data array is 
then plotted as a bar graph with the atoms array as the tick label. Lastly, the ligand RMSF script prints the 
significant differences as a 2 column matrix with the atom number in the first and the difference value in 
the second column.       
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Figure 6. 10: Removing zeros from significant differences 
 
6.2.4  Van  der  Waals  Interactions    
A script for van der Waals interactions was written in MATLAB to process interaction data from 
a file generated through the Schiffer Laboratory's GFortran script. The GFortran script imports the data 
from the simulation and outputs a file with the extension, vdwen, that has varying columns and rows 
depending on the frame. The primary challenge with this file type is accounting for rows that are used as 
sub headers for each frame and a varying amount of residues within the frame.  
The files were first imported based on their file location and data extracted using textscan. 
MATLAB’s string trim function, “strtrim”, was used to remove the white space surrounding the numbers 
and characters in the file. Numeric strings were then converted into numbers and non-numeric values, 
such as “Frame n of x” and residue names, were removed. Data was then split into proper cell columns 
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and non-numeric cells were overwritten with “NaN” or not a number (Fig. 6.11). Cell columns were then 
converted to matrices and temporary variables were cleared to preserve program memory and increase 
script speed. The same textscan steps and for loops were conducted to initialize all 12 data files.       
  
Figure 6. 11: van der Waals script loading .vdwen files and extracting data 
 
     Data for each mutation was contained in three columns of interest: Chain, ResNum or residue 
number and Energy. The data was divided into chain A and B for each mutation through a for loop that 
read each line of data for the length of the chain array (Fig. 6.12). First, the for loop determined which 
chain the energy value belonged to based on whether there was an “A” or “B” string as the value in the 
chain data array. If the number was not equal to 1200, the placeholder for the rows of frame sub headers, 
the for loop continued. If the mutation/wild type data matrix was empty, the energy was appended into the 
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matrix. In the figure below, this data matrix is either Mut1ChainA or Mut1ChainB. If there was a 
previous energy in the matrix for that residue, the energies were averaged in place. The data matrix 
consisted of four columns: the residue number, averaged replicate 1 energies, averaged replicate 2 
energies, and averaged replicate 3 energies. Similar for loops were conducted for each mutation and wild 
type. 
  
Figure 6. 12: Separating van der Waals energies into chain A and B data sets and averaging in place 
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     Bar graphs for each mutation were generated and the average van der Waals energies of each 
residue across the three replicates was calculated.  
6.2.5  Hydrogen  Bonds  
     A script for hydrogen bond percentages was written to accommodate comma separated value 
files. The script utilizes .csv files that are directly outputed from the MD simulations in Desmond. These 
.csv files contains a list of HIV-1 protease residues that exhibit hydrogen bonding at each time point 
during the simulation. The goal of hydrogen bond analysis is to determine any changes between active 
site interactions when mutations are present.  
In order to achieve this, each mutation replicate was imported into the program. The percentage 
of hydrogen bonding was determined by scanning through each file to determine how many times the 
similar residues appear during the 500 frames. The amount of times each specific residue appeared was 
stored in an array. The total appearances were then divided by the total amount of frames to determine the 
hydrogen bond percentage throughout the simulation. 
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Figure 6. 13: Portion of hydrogen bonding percentage 
 
 
6.2.6 Alpha-Carbon Distances 
A script for organizing C-alpha distances was developed using MATLAB. The C-alpha distances 
data files were .csv files for each mutation. Each comma separated value file had the time steps, which 
designated each frame of the 500 frames for a 100 nanosecond simulation, as the first column. The six 
following columns were for each type of measurement that included the distances between residues 25 to 
25’, 84 to 84’, 25 to 50, 25’ to 50’, 25’ to 50, and 25 to 50’. The residue numbers without the prime 
symbol are the residues of chain A and the residue numbers with the prime symbol are residues of chain 
B.  
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In the MATLAB script, the data from the comma separated value files for each replicate of each 
mutation were imported, which an example is seen in Figure 6.14. 
 
  
Figure  6.  14:  I84V  C-­‐‑alpha  distances 
 
 
Once all the data for each replicate and mutation were imported, the histograms of each C-alpha 
measurement were developed. The bins for the histograms were made according to the data. For example, 
the C-alpha distances between the catalytics residues (25-25’) fell in a range of 5 Angstroms to 7.5 
Angstroms.The bins were separated between a value of 0.5 Angstroms. Next, histograms were created for 
each replicate of each HIV-1 protease variant using the bins specified. An example for wild type C-alpha 
distances between the catalytic residues are shown below. 
 
  
Figure 6. 15: C-alpha Histograms 
 
 
The average of each of the variant’s histogram was taken, which is seen in Figure 6.16. 
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Figure 6. 16: Histogram averages 
 
 
The averages of each variant’s C-alpha distances were then compiled together for comparison 
between the different variants. Six graphs were created for each type of C-alpha distance. To illustrate, 
the script for the graph of the C-alpha distances between the catalytic residues are shown in Figure 6.17. 
 
  
Figure 6. 17: C-alpha distances plots compilation 
 
 
The graphs of the C-alpha distances were put into a figure of 6 different graphs, which is shown 
C-alpha Distances Results in Chapter 5. The script developed for the C-alpha Distances can be further 
modified for different mutations, number of replicates, and different input files.  
 
6.2.7 Modification of PDB File 
     To display the protein RMSF values visually on the cartoon display of the protein, the PDB files 
needed to be modified. The beta-factors of the PDB file can be displayed on a color spectrum in the 
computer program PyMol, which is a three-dimensional molecular program. The beta-factors can be 
modified to any values desired. However, the PDB file’s structure is unique and therefore cannot be easily 
imported and modified using MATLAB. The goal of the Python script was used to read the PDB file and 
create an output file of the protein RMSF values that correspond the protein RMSF value for each atom.  
Protein RMSF values are designated to each residue, but the PDB file has a beta-factor for each 
atom. Therefore, the protein RMSF value needs to be repeated for each atom of the residue, which each 
type of residue has a different number of atoms in it. To obtain the number of atoms for each residue, the 
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Python script counts how many atoms are in each residue. The reading of the PDB file and obtaining the 
number of atoms for each residue is shown in Figure 6.18. 
  
Figure 6. 18: Beta Factor Modification 
 
This section of the Python script reads the pdb file using the function “open.” Empty arrays for 
chain A and chain B are defined because they will create a list of the residue numbers of each atom. For 
example, if residue 12 has eight atoms, then the number 12 will appear eight times in the array. Next, 
each line is read in the pdb. There are several column in the PDB file, so the “line.split()” function splits 
the line into columns. The script then looks at the first column with the function “list[0]”  and checks if it 
says ‘ATOM’ with if statement “if id ==  ‘ATOM.’ There are several other atoms in the PDB file, such as 
water molecules, but atoms of the protein are labeled ‘ATOM’. Then the chain letter in column 4 is read 
and if it is an ‘A’, then the residue number in column 5 is copied into the chain A array, and respectively 
if it is a ‘B.’ Along with having the PDB file read and the arrays being filled, the RMSF values need to be 
imported into the function also. This section of the script is shown in Figure 6.19.  
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Figure 6. 19: Protein RMSF Text File Import 
 
The data of the file were imported with the function “open” and each line of the file, which was 
the protein RMSF values, were imported into an array named “rmsf”. The next step of the script was to 
create a new array of numbers that put the protein RMSF value with its corresponding atom, which is 
shown in Figure 6.20. 
  
Figure 6. 20: Data array corresponding to PDB file 
 
Two new arrays for the protein RMSF values that correspond to the order and number of atoms in 
the PDB file are labeled as “BfacChainA” for chain A and “BfacChainB” for chain B. The while loop 
goes through the list of residue numbers created from pdb file, which repeats the same residue number for 
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the number of atoms in the residue, and matches the correct RMSF value for the residue. The resulting 
lists, for each chain, have the respective RMSF value for each atom. The last section of the script outputs 
these lists into a text file, which is shown in Figure 6.21. 
  
Figure 6. 21: Outputs Protein RMSF for each atom of PDB 
 
An outfile is created with the function write, which is signified by “w.” The protein RMSF values 
that will be exported are converted into a column of strings with the for loop and inserted in the new 
arrays labeled as “OutChainA” for chain A and “OutChainB” for chain B. Next, the new arrays are put 
together in another array labeled as “OutFileData.” The combined array is exported into the outfile with 
the command “writelines” and closed to successfully create the text file.  
The values in the outfile file are copied into the PDB file in the column of the beta-factors. The 
newly modified PDB file can then be uploaded in PyMol and colored according to the protein RMSF 
values, which is referenced as the beta-factors in the PyMol software. 
6.3 Relevant Industry Standards Met 
     Our project was research based within a graduate school laboratory. The molecular dynamic 
approach to computationally evaluating protein dynamics is utilized in many protein based research labs. 
However, there is minimal regulation between different laboratories due to differences in molecular 
dynamic software and protocols. Currently, there are no overarching regulations for educational based 
research using molecular dynamic simulations. Although, commercial biologics companies are held to an 
ISO standard. Industry is limited to regulation from the biomimetics ISO standard 18458:2015 [58]. This 
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ISO standard outlines common programming languages, a terminology framework, and provides a proper 
definition of a biomimetics systems. Standards for this type of computational analysis are limited due to 
the recent advances in this technology.      
6.4 Design Considerations 
6.4.1 Economics 
 
     Our project is based on the computational analysis of drug resistance patterns within viral HIV-1 
protease. The project’s goal was to identify any common patterns that resulted in proper protein function 
in the presence of protease inhibitors. The project was strictly theoretical research which could be applied 
to protease inhibitor design. However, if protease inhibitors were to be designed based off this research 
the drug would be substantially more expensive than the average HIV-1 treatment. HIV-1 treatment for 
affected patients can cost upwards of $23,000 annually and can be higher depending on using name 
brands [9]. Currently, the most potent protease inhibitor commercially available is Darunavir which 
typically costs $1,500 per month [30]. Protease inhibitors based off this research would exhibit potency 
greater than Darunavir, which would make this treatment more expensive.  
6.4.2 Environmental Impact 
     
     Our project is completely computationally based only utilizing computers for analysis. Although 
convenient for the data analysis, computers contribute to a greater environmental impact than expected. 
Firstly, the manufacturing process consumes high amounts of electricity and consists of processing heavy 
metals and toxic chemicals. Secondly, once obtained and in the lab, the computers used to run simulations 
use high amounts of electricity and are inefficient due to their age. Lastly, if the computers used to 
complete this project are upgraded in the future, there is significant environmental impact involved in 
their disposable.       
 
6.4.3 Societal Influence 
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     Promising drug resistance related research, including this project, can provide hope within society 
as a whole. For many generations of human existence the contraction of a disease, such as HIV, inevitably 
resulted in death. Current problems facing modern drug use for disease treatment is resistance, which can 
provoke fear across a society. Being able to report findings that show drug resistance can be determined 
and accounted for in drug production is very hopeful. This type of research will allow ordinary people 
with peace of mind if they contract any type of viral disease.  
6.4.4 Political ramifications 
 
Some political ramifications that might concern this project is the funding and which types of 
HIV we examine drug resistance for. The lab’s funding might have an obligation to research certain types 
of HIV.  In our case, it’s HIV-1 that affects the majority of the HIV population within the United States 
and western world. 
6.4.5 Ethical concern 
 
This project only focuses on one serotype of HIV and is neglecting other forms that are prevalent 
throughout third world countries. Although we are focusing on the majority of the population with HIV 
(HIV-1), we do not consider the others.  
6.4.6 Health and safety 
 
Specifically this project does not pose any health or safety issues. The research and analysis are 
all executed on computer programs.  
However, there are several health and safety issues with researching drug resistance. Our project 
requires a crystal structure of the protein, which is the PDB for the molecular software. This PDB gives 
different energy parameters and atom coordinates that dictate the protein’s behavior in the simulations. 
The making of the crystal structure poses some health and safety risks from obtaining the protein and 
manipulating the protein into growing a crystal, as the operator is in contact with the virus. This crystal is 
then examined by Nuclear Magnetic Resonance imaging (NMR) and solved, with molecular software, to 
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determine the atomic structure and energies of the protein. Although there is associated risks with 
developing the crystal structure, overall, computational approaches pose significantly reduce health 
related risks. 
6.4.7 Manufacturability 
     This project is not manufacturable, rather is intended to be used as a research resource. The 
program written in MATLAB with a supplemental python script that could be reproduced and altered 
towards specific research aims. Manufacturing could be considered if this research was to be conducted 
with collaborative labs to provide consistent experimentation. 
6.4.8 Sustainability 
     The analysis program produced through this project is sustainable, as it can be easily adapted 
towards specific needs. Code variables were kept vague intentionally so it can be a sustainable analysis 
solution used for a variety of mutations and tests. Another factor that plays a role in sustainability is 
software updates, both in terms of molecular modeling programs and scripting languages. 
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7.0 Discussion 
In an effort to elucidate potential resistance patterns that specific mutations to HIV-1 protease 
create, the team performed molecular dynamic studies. Further analysis was conducted using information 
obtained from molecular dynamic simulations separated into two categories: inhibitor movement analysis 
and inhibitor interactions analysis. Inhibitor movement analysis quantifies the effectiveness of protein and 
ligand binding through molecular movement. Protein-ligand RMSD, protein RMSF, ligand RMSF, and 
alpha carbon distances were the dynamic factors investigated that attribute to drug resistance. However, 
inhibitor interactions analysis quantifies the effectiveness of protein and ligand binding through atomic 
interactions. van der Waals and hydrogen bond percentages were the interactive factors investigated that 
attribute to drug resistance.   
7.1 Inhibitor Movement Analysis 
7.1.1 Protein-Ligand RMSD 
Protein-Ligand RMSD was the first analysis that needed to be conducted before progressing to 
further stages of analysis.  This dynamic attribute between the protein and ligand directly correlates to 
protein stability, thus feasibility in vivo. If the RMSD values are either too high or low, information 
gathered from the simulation is irrelevant due to the lack of equilibrium. The Schiffer Lab has determined 
that relevant information can be obtained from HIV-1 protease RMSD values that equilibrate between 
roughly 1-1.5 angstroms over the course of 100 nanosecond simulations.  The average protein-ligand 
RMSD plots for wild type, I84V, V82F+I84V, and M46I+V82F+I84V variants all met this requirement. 
All further analysis was determined to be valid. 
7.1.2 Protein RMSF 
 The protein RMSF was analyzed to determine the average protein mobility across the simulation. 
This takes the dynamic nature of the protein into account, allowing residues with the most movement and 
fluctuation from their starting position to be easily identified. With the exception of V82F+I84V chain B, 
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residues 1 and 2, RMSF values of each replicate were consistent, varying slightly due to natural in vivo 
movement. This supports our original choice of computational analysis and molecular dynamics, as the 
differences depicted in each RMSF replicate demonstrate the dynamic process is being accurately 
simulated.  
When comparing average RMSF values, each mutant variant followed a similar trend, with some 
difference observed at residues 1-5, 15-18, 50-60, 70-75, 99-104 (chain B, residues 1-5), and 150-160. 
The differences seen in residues 1-5 in both chains is to be expected, as that is the dimerization region, 
which is highly motile. The fluctuation observed in the 10’s loop, residues 16-18, was present in all three 
mutations. I84V and V82F+I84V had more fluctuation through the 10s loop compared to the wild type. 
Conversely, M46I+V82F+I84V exhibited a more rigid 10’s loop with a negative change in angstroms 
compared to wild type. Fluctuation in residues in the flap regions, residues 50-60 and 150-160, were 
observed in all three variants. M46I+V82F+I84 had the greatest change in fluctuation compared to wild 
type, followed by I84V then V82F+I84V. Interestingly, the change in RMSF in V82F+I84V compared to 
wild type was not significant for these residues, although is visible when comparing the heatmaps. This is 
most likely caused by the variation among the wild type values for those residues, as significance was 
determined through wild type standard deviation. The flap region is expected to be a very dynamic region 
of the protein and this may be a source of possible error, as the change in RMSF for V82F+I84V may be 
greater than shown depending on the variation in wild type replicates. The final residues where a 
significant difference in RMSF was observed was in residues 70-75, the back of the beta sheet in chain A. 
Although difficult to observe on the heat maps, there is fluctuation through this area, especially in 
V82F+I84V. In V82F+I84V, at residue 70, the values are significantly negative, and change to 
significantly positive the next residue. This varies from what was observed in I84V and 
M46I+V82F+I84V, which had a negative RMSF difference compared to wild type.  
Lastly, RMSF values of each variant and wild type were summed. V82F+I84V had the lowest 
total RMSF, however, when comparing to the protein RMSF significant differences bar graph, the 
majority of the RMSF values were greater than the wild type RMSF, giving a negative RMSF difference. 
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Although in some instances M46I+V82F+I84V had the greatest difference from wild type, when 
compared to the summed RMSF values, it most closely matched wild type. This suggests rigidity may 
play a role in conferring drug resistance, as V82F+I84V was the most rigid structure over the 500ns but 
had the greatest total difference to wild type.   
7.1.3 Ligand RMSF 
 Ligand RMSF was analyzed to determine the effects of the mutant variants on inhibitor mobility. 
Average ligand RMSF follows a general trend with the wild type having the lowest fluctuation, followed 
by I84V, then V82F+I84V, and M46I+V82F+I84V with the greatest fluctuation. The most significant 
differences from wild type occur at atom numbers 9-19, 25 and 26, and 32-38. Atoms 9-19 include two 
double bonded oxygen atoms at numbers 9 and 10 to a sulfur atom and an oxygen bound to a carbon atom 
at 18. The fluctuation in these atoms was primarily observed in M46I+V82+I84V. V82F+I84V had one 
significant difference compared to wild type in this atom range at atom 15, the carbon oxygen is bound to. 
However, at atoms 25 and 26, V82F+I84V is the only variant with a significant RMSF difference. The 
most fluctuation was observed in atoms 32-38, with M46I+V82F+I84V having the greatest fluctuation, 
more than double that of I84V and V82F+I84V at atoms 34, 35, 36, and 37.  
 The RMSF values of each variant were also summed and followed an increasing trend with wild 
type having the lowest total RMSF and M46I+V82F+I84V the greatest. When considering the difference 
to wild type bar graph, the same pattern is followed with very few instances of a negative ligand RMSF 
difference. 
7.1.4 Alpha Carbon Distances 
The carbon-alpha distances between several residues across the active site of all variants of HIV-
1 protease were measured and analyzed. These distances were between residues 25-25’, 84-84’, 25-50, 
25-50’, 25’-50, and 25’-50’. The average distances between the residues were calculated for each variant. 
The average distances of the mutated variants were then compared to the wild type distances. The 
significant findings of this comparison is that the active site decreased in size with the mutated variants. 
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However, C-alpha distances of the M46I+V82F+I84V variant and the V82F+I84V variant were closer to 
the wild type, while the I84V C-alpha distances were smaller compared to wild type. This suggests that 
the active site size of the M46I+V82F+I84V variant and the V82F+I84V variant are closer to wild type, 
while the I84V active site size was smaller compared to wild type. 
7.2 Inhibitor Interactions Analysis 
7.2.1 Van der Waals 
Van der Waals interactions are one of the intermolecular forces that keep the ligand attached to 
the protein. Thus, the changes in van der Waals energies due to mutations directly impact the interactions 
between the ligand and the protein. These energies were calculated between the ligand atoms and the 
protein residues for each HIV-1 protease variant. Between the different replicates of each variant of the 
protein, the difference in van der Waals energies were small and thus showing a consistent behavior 
between replicates. 
To compare the mutated variants’ van der Waals energies to the wild type, the average mutated 
variant van der Waals were subtracted from the average wild type. Several differences were seen between 
the mutated variants’ van der Waals energies. However, many of these differences were insignificant, 
which we decided was less than a difference of 0.02 kcal/mol.  
The significant differences between the mutated variants and the wild type for chain A were seen 
in residues 27-29,47-50, 81, and 84.  Residues 27 to 29 are located at the bottom of the active site. The 
positive differences in residue 27 for all mutated variants suggest a stronger interaction between the 
ligand and the residue. V82F+I84V had the largest increase, with M46I+V82F+I84V following and I84V 
with the least increase. However, the negative differences in residue 28 and 29 for all mutated variants 
suggest a stronger interaction between the ligand and the residue.  
Residues 47 to 50 are located at the top of the active site. For residue 47 and 48, the only variant 
that had a significant difference was V82F+I84V. V82F+I84V mutation caused a decrease in van der 
Waals energies between the ligand and residues 47 and 48. Both V82F+I84V and I84V mutations caused 
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a decrease in van der Waals energies between the ligand and residue 49, but V82F+I84V had a much 
larger decrease. However, all mutated variants had a stronger interaction between the ligand and residue 
50, which is the residue at the tip of the flap. 
 For residue 81, only the I84V mutation showed a significant difference of the van der Waals 
energies. The difference was negative and thus suggesting a decreased interaction between the ligand and 
the residue. Residue 84 was changed for each mutated variant in the team’s project and each mutated 
variant showed a large decrease in van der Waals energies. This suggests that a mutation in residue 84 has 
a significant impact on the interaction between the ligand and the protein. 
Van der Waals energy changes were also seen in Chain B. Significant differences were seen in 
residues 8, 25-28, 49, 50, 81, 82, and 84. Residue 8 is located below the active site, but the isoleucine 
amino acid reaches into the active site. Only mutated variant V82F+I84V had a significant difference in 
van der Waals energies between the ligand and the protein. The difference is negative, which suggests a 
stronger interaction between the ligand and the protein. Residues 25 to 28 of chain B also experienced 
significant difference in van der Waals energies compared to wild type. Residue 25 is the catalytic residue 
of the protein and only mutated variant V82F+I84V had a significant difference in van der Waals energies 
for that residue. V82F+I84V had a large increase in van der Waals energies, suggesting that the 
interaction between the ligand and that residue increased. Van der Waals energies of residue 26 compared 
to wild type experienced a large increase for V82F+I84V variant and a significant decrease for the I84V 
variant. Residue 28 had a significant decrease for all mutated variants, with I84V having the largest 
decrease, followed by M46I+V82F+I84V and lastly V82F+I84V. 
Residues 49 and 50 also show significant differences in the van der Waals energies of chain B. 
All mutated variants experience an increased significant difference in van der Waals energies of residue 
49 compared to wild type. This suggests an decrease in the strength of the interaction between the ligand 
and residue 49. Yet, only M46I+V82F+I84V mutated variant had a significant difference in van der 
Waals energies compared to wild type for residue 50. The difference was negative, suggesting the 
interaction strength between the tip of the flap (residue 50) and the ligand increased. 
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Residues 81, 82, and 84 experienced significant differences in van der Waals energies between 
the mutated variants and the wild type. They are all located in the active site. Residue 81 had a significant 
difference with only the I84V mutated variant. The difference was negative, which suggests a increased 
interaction between the ligand and residue 81. Residue 82 had a significant difference in only V82F+I84V 
mutated variant. The difference was also negative, which suggests an increased interaction between the 
ligand and residue 82. Residue 84 had large significant differences between all mutated variants. 
V82F+I84V had the largest negative difference with M46I+V82F+I84V closely following. I84V had the 
least negative difference. 
Overall, there were no significant patterns between the different variants of the protein. The only 
distinction seen was that the mutation of residue 84 had a large impact on the van der Waals energies. 
7.2.2 Hydrogen Bonds 
 Hydrogen bond percentages were analyzed since they play a major role in inhibitor binding. 
Darunavir, the most potent protease inhibitor commercially available, was chosen as the modeling ligand 
since it’s mechanism of binding relies heavily on hydrogen bonding. Molecular dynamic analysis 
provided the team with 7 active site residues (4 chain A and 3 chain B) that exhibit hydrogen bondage to 
the ligand. The residues that displayed the most significant changes across variants compared to wild type 
were chain A residues 25, 29, and 30 as well as chain B residue 50. Chain A residue 25 , aspartic acid, is 
the catalytic component that facilitates peptide bond cleavage.  
The I84V variant displayed notable interaction related drug resistance with a 43.7% decrease in 
hydrogen bonds compared to wild type. Although, both I84V+V82F and M46I+V82F+I84V variants 
increase inhibitor binding efficacy with 17.3% and 41.3% bondage increase. The I84V single point 
mutation switching isoleucine with valine provided the change necessary to alter the binding domain such 
that the aspartic acid residue had a difficult time creating hydrogen bonds with the oxygen atom (18) on 
the ligand. I84V+V82F and M46I+V82F+I84V variants were capable of changing the binding pocket 
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conformation such that the aspartic acid residue was in a closer proximity to the ligands oxygen atom (18) 
resulting in a high degree of stability.  
Another noteworthy hydrogen bond based interaction was the negative effect of 
M46I+V82F+I84V variant on chain A residue 29 bondage. Wild type, I84V, and I84V+V82F variants all 
displayed a high degree of hydrogen bonding with 96%, 96.5%, and 97.2%, respectively. Yet, the 
M46I+V82F+I84V variant decreased residue 29’s hydrogen binding affinity to the oxygen atom (28) of 
the ligand by 30.1%.  Residue 29 on chain B is an aspartic acid that is a catalytic component. The M46I 
mutation caused a binding pocket change great enough to increase the distance between chain A residue 
29 and the oxygen atom (28) of the ligand. 
Additionally, the hydrogen bonding affinities for chain B residue 50 to the oxygen atom (9) of the 
ligand varied between variants. Reside 50 is isoleucine that plays a minimal role in hydrogen bondage 
displaying 16.5% bondage in wild type. The single I84V point mutation increased hydrogen bondage by 
6.4% while I84V+V82F and M46I+V82F+I84V variants decreased bondage by 6.9% and 14.4% 
respectively.  
Finally, all of the residues contributing hydrogen bonding in each variant were summed then 
analyzed for overall trends. As expected, the wild type had the highest summed percentage of bonding 
totaling 426.4%. Similarly, the I84V+V82F variant retained a high degree of hydrogen bondage with a 
summed percentage of 423.6%. The I84V variant displayed a significant drop of  47.1% in summed 
hydrogen bond affinity compared I84V+V82F.  The I84V variant had an overall summed hydrogen bond 
percentage of 376.5%. The M46I+V82F+I84V variant showed the least total amount of hydrogen 
bondage with 331.3%, a 95.1% decrease compared to wild type.        
Based on the total hydrogen bonding percentages, the M46I+V82F+I84V variant displayed the 
greatest drug resistance.   
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8.0 Conclusions and Recommendations 
 
The team successfully simulated three mutated variants of HIV-1 protease and developed 
programs to efficiently interpret the inhibitor interaction data and the protein dynamic behavior. These 
programs were used to compare and present the data in a manner where conclusions could be drawn. The 
significant findings of this analysis and recommendations for future work are discussed in this chapter. 
8.1 Significant Findings 
 
The team hypothesized there would be a difference in inhibitor interactions and protein dynamic 
behavior in mutant variants compared to wild type. Specifically, as the number of mutations increased, it 
was thought there would be increased drug resistance. Ligand RMSF data may support this; however, 
further analysis displayed inconsistent trends with respect to drug resistance. V82F+I84V showed the 
most inhibitor fluctuation compared to wild type, followed by M46I+V82F+I84V, and I84V. However, in 
the case of protein RMSF, van der Waals interactions and hydrogen bond percentages, increasing 
resistance is not supported. Van der Waals interactions provided inconclusive data, with all variants 
having a similar amount of energies. With respect to protein RMSF, V82F+I84V had the greatest 
fluctuation compared to wild type, followed by M46I+V82F+I84V, then I84V. Similar to protein RMSF, 
V82F+I84V demonstrated the highest percentage of hydrogen bonds of the mutant variants, followed by 
M46I+V82F+I84V, then I84V. This however, partially supports the hypothesis, as bond percentages 
decreased from V82F+I84V to M46I+V82F+I84V.    
8.2 Future Direction 
 
Although, this project provided insightful results, there is additional research that can be 
conducted to strengthen our conclusions. Due to time constraints and feasibility, the team was limited to 
analysis of only three mutated variants. We suggest further MD analysis of different single point 
mutations within the active site to investigate whether increased mutations increase drug resistance. 
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Specifically, V82F and M46I single point mutations should be analyzed to determine their roles in 
compounded mutation resistance. Additionally, non-active site mutations should be examined to 
determine their effect on protein-ligand affinity. Evaluating different simulation parameters can 
strengthen future behavior patterns. Finally, the data generated from this project can be used in the 
development of protease inhibitors that are designed to retain potency across compounded mutations that 
may confer increased resistance. 
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Appendix A 
 
 The team created a Gantt chart to make sure the project is completed within time constraints 
(Figures A.1 through A.4).   
A.1 A Term Gantt Chart 
 
 
 
Figure A.1: A Term Gantt Chart 
 
 
A.2 B Term Gantt Chart 
 
 
Figure A.2: B Term Gantt Chart 
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A.3 C Term Gantt Chart 
  
 
Figure A.3: C Term Gantt Chart 
 
A.4 D Term Gantt Chart 
 
 
Figure A.4: D Term Gantt Chart 
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Appendix B 
B.1  Protein-­‐‑Ligand  RMSD  Script  
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